Clinical Management Guide for CBS/PSP

Migration, Crosslink

📖

Clinical Management Guide for CBS/PSP

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-clinical-management-gu

📖 Wiki Page

therapeutic15224 wordssynced 2026-04-02

Clinical Management Guide for CBS/PSP

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Clinical Management Guide for CBS/PSP</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Donepezil (Aricept)</td>
<td>AChE inhibition</td>
</tr>
<tr>
<td class="label">Rivastigmine (Exelon)</td>
<td>AChE + BuChE inhibition</td>
</tr>
<tr>
<td class="label">Galantamine (Razadyne)</td>
<td>AChE + allosteric modulation</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Memantine (Namenda)</td>
<td>NMDA receptor antagonism</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Sertraline (Zoloft)</td>
<td>Depression, anxiety</td>
</tr>
<tr>
<td class="label">Escitalopram (Lexapro)</td>
<td>Depression, anxiety</td>
</tr>
<tr>
<td class="label">Fluoxetine (Prozac)</td>
<td>Depression</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Class</td>
</tr>
<tr>
<td class="label">Venlafaxine (Effexor)</td>
<td>SNRI</td>
</tr>
<tr>
<td class="label">Bupropion (Wellbutrin)</td>
<td>NDRI</td>
</tr>
<tr>
<td class="label">Mirtazapine (Remeron)</td>
<td>NaSSA</td>
</tr>
<tr>
<td class="label">Trazodone</td>
<td>SARI</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Indication</td>
</tr>
<tr>
<td class="label

...

Clinical Management Guide for CBS/PSP

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Clinical Management Guide for CBS/PSP</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Donepezil (Aricept)</td>
<td>AChE inhibition</td>
</tr>
<tr>
<td class="label">Rivastigmine (Exelon)</td>
<td>AChE + BuChE inhibition</td>
</tr>
<tr>
<td class="label">Galantamine (Razadyne)</td>
<td>AChE + allosteric modulation</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Memantine (Namenda)</td>
<td>NMDA receptor antagonism</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Sertraline (Zoloft)</td>
<td>Depression, anxiety</td>
</tr>
<tr>
<td class="label">Escitalopram (Lexapro)</td>
<td>Depression, anxiety</td>
</tr>
<tr>
<td class="label">Fluoxetine (Prozac)</td>
<td>Depression</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Class</td>
</tr>
<tr>
<td class="label">Venlafaxine (Effexor)</td>
<td>SNRI</td>
</tr>
<tr>
<td class="label">Bupropion (Wellbutrin)</td>
<td>NDRI</td>
</tr>
<tr>
<td class="label">Mirtazapine (Remeron)</td>
<td>NaSSA</td>
</tr>
<tr>
<td class="label">Trazodone</td>
<td>SARI</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Valproic acid (Depakote)</td>
<td>Mania, mood stabilization</td>
</tr>
<tr>
<td class="label">Lamotrigine (Lamictal)</td>
<td>Mood stabilization</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>Bipolar, mood</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Pimavanserin</td>
<td>5-HT2A inverse agonist</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Quetiapine</td>
<td>D2 blockade (transient)</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Clozapine</td>
<td>D4 > D2 blockade</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Reason</td>
</tr>
<tr>
<td class="label">Haloperidol (Haldol)</td>
<td>Classic antipsychotic — severe worsening</td>
</tr>
<tr>
<td class="label">Risperidone (Risperdal)</td>
<td>Significant motor worsening</td>
</tr>
<tr>
<td class="label">Olanzapine (Zyprexa)</td>
<td>Significant motor worsening</td>
</tr>
<tr>
<td class="label">Aripiprazole (Abilify)</td>
<td>Partial agonist — unpredictable</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>First Choice</td>
</tr>
<tr>
<td class="label">Sleep hygiene</td>
<td>CBT-I</td>
</tr>
<tr>
<td class="label">Melatonin</td>
<td>1-10mg nightly</td>
</tr>
<tr>
<td class="label">Trazodone</td>
<td>25-50mg nightly</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Clonazepam</td>
<td>0.25-1mg nightly</td>
</tr>
<tr>
<td class="label">Melatonin</td>
<td>3-12mg nightly</td>
</tr>
<tr>
<td class="label">Pramipexole</td>
<td>0.125-0.75mg</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>Notes</td>
</tr>
<tr>
<td class="label">Modafinil</td>
<td>May help EDS; limited PD data</td>
</tr>
<tr>
<td class="label">Sunlight exposure</td>
<td>First-line — circadian regulation</td>
</tr>
<tr>
<td class="label">Exercise</td>
<td>Helps sleep quality</td>
</tr>
<tr>
<td class="label">Avoid sedating meds</td>
<td>Reduce benzodiazepines, opioids</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Evidence</td>
</tr>
<tr>
<td class="label">CBT</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">Mindfulness/meditation</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Exercise</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">Peer support groups</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Buspirone</td>
<td>Generalized anxiety</td>
</tr>
<tr>
<td class="label">Escitalopram</td>
<td>Anxiety disorder</td>
</tr>
<tr>
<td class="label">Lorazepam</td>
<td>Acute anxiety</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Description</td>
</tr>
<tr>
<td class="label">In-home respite</td>
<td>Professional caregiver comes to your home</td>
</tr>
<tr>
<td class="label">Adult day programs</td>
<td>Facility-based care during daytime hours</td>
</tr>
<tr>
<td class="label">Short-term nursing facility</td>
<td>Temporary stay in care facility</td>
</tr>
<tr>
<td class="label">Family/friends</td>
<td>Help from trusted individuals</td>
</tr>
<tr>
<td class="label">Resource</td>
<td>Contact</td>
</tr>
<tr>
<td class="label">CurePSP</td>
<td>curepsp.org / 1-800-457-4777</td>
</tr>
<tr>
<td class="label">Parkinson's Foundation</td>
<td>parkinson.org / 1-800-4PD-INFO</td>
</tr>
<tr>
<td class="label">ARCH Respite</td>
<td>archrespite.org</td>
</tr>
<tr>
<td class="label">Social Security</td>
<td>ssa.gov</td>
</tr>
<tr>
<td class="label">Medicare</td>
<td>medicare.gov</td>
</tr>
<tr>
<td class="label">Care.com</td>
<td>care.com</td>
</tr>
<tr>
<td class="label">Family Caregiver Alliance</td>
<td>caregiver.org</td>
</tr>
<tr>
<td class="label">AARP Caregiving</td>
<td>aarp.org/caregiving</td>
</tr>
<tr>
<td class="label">Modification</td>
<td>Purpose</td>
</tr>
<tr>
<td class="label">Simplified living space</td>
<td>Reduce confusion</td>
</tr>
<tr>
<td class="label">Contrast enhancements</td>
<td>Help visuospatial deficits</td>
</tr>
<tr>
<td class="label">Grab bars, ramps</td>
<td>Fall prevention</td>
</tr>
<tr>
<td class="label">Daily routines</td>
<td>Reduce anxiety</td>
</tr>
<tr>
<td class="label">Priority</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">1</td>
<td>Pimavanserin</td>
</tr>
<tr>
<td class="label">2</td>
<td>SSRI (sertraline)</td>
</tr>
<tr>
<td class="label">3</td>
<td>Donepezil</td>
</tr>
<tr>
<td class="label">4</td>
<td>Melatonin</td>
</tr>
<tr>
<td class="label">5</td>
<td>CBT + support</td>
</tr>
<tr>
<td class="label">6</td>
<td>Avoid typical antipsychotics</td>
</tr>
<tr>
<td class="label">Medication</td>
<td>Levodopa Interaction</td>
</tr>
<tr>
<td class="label">Sertraline</td>
<td>Minimal</td>
</tr>
<tr>
<td class="label">Pimavanserin</td>
<td>Minimal</td>
</tr>
<tr>
<td class="label">Quetiapine</td>
<td>Minimal</td>
</tr>
<tr>
<td class="label">Trazodone</td>
<td>Minimal</td>
</tr>
<tr>
<td class="label">Avoid: MAOIs</td>
<td>Hypertensive crisis</td>
</tr>
<tr>
<td class="label">Pain Type</td>
<td>Prevalence</td>
</tr>
<tr>
<td class="label">Musculoskeletal</td>
<td>50-60%</td>
</tr>
<tr>
<td class="label">Dystonic</td>
<td>40-50%</td>
</tr>
<tr>
<td class="label">Radiculopathy</td>
<td>20-30%</td>
</tr>
<tr>
<td class="label">Central (thalamic)</td>
<td>15-25%</td>
</tr>
<tr>
<td class="label">Neuropathic</td>
<td>15-20%</td>
</tr>
<tr>
<td class="label">Medication</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Gabapentin</td>
<td>300-900mg TID</td>
</tr>
<tr>
<td class="label">Pregabalin</td>
<td>75-150mg BID</td>
</tr>
<tr>
<td class="label">Duloxetine</td>
<td>30-60mg daily</td>
</tr>
<tr>
<td class="label">Medication</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Tramadol</td>
<td>50-100mg q6h PRN</td>
</tr>
<tr>
<td class="label">Oxycodone</td>
<td>5-10mg q6h PRN</td>
</tr>
<tr>
<td class="label">Acetaminophen</td>
<td>650-1000mg q6h</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>Evidence</td>
</tr>
<tr>
<td class="label">Physical Therapy</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">Heat/Cold Therapy</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">TENS (Transcutaneous Electrical Nerve Stimulation)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Massage Therapy</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Acupuncture</td>
<td>Mixed</td>
</tr>
<tr>
<td class="label">Assistive Devices</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">Tool</td>
<td>Description</td>
</tr>
<tr>
<td class="label">VAS (Visual Analog Scale)</td>
<td>0-10 pain rating</td>
</tr>
<tr>
<td class="label">PDQ-39 Pain Subscale</td>
<td>Disease-specific</td>
</tr>
<tr>
<td class="label">Brief Pain Inventory</td>
<td>Multi-dimensional</td>
</tr>
<tr>
<td class="label">McGill Pain Questionnaire</td>
<td>Detailed descriptors</td>
</tr>
<tr>
<td class="label">Pain Medication</td>
<td>Levodopa Interaction</td>
</tr>
<tr>
<td class="label">Gabapentin</td>
<td>Minimal</td>
</tr>
<tr>
<td class="label">Pregabalin</td>
<td>Minimal</td>
</tr>
<tr>
<td class="label">Duloxetine</td>
<td>Minimal</td>
</tr>
<tr>
<td class="label">Tramadol</td>
<td>Minimal</td>
</tr>
<tr>
<td class="label">Oxycodone</td>
<td>Enhanced sedation</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Finding</td>
</tr>
<tr>
<td class="label">Motor symptoms</td>
<td>Mild improvement in UPDRS motor scores</td>
</tr>
<tr>
<td class="label">Pain management</td>
<td>Moderate pain reduction</td>
</tr>
<tr>
<td class="label">Sleep quality</td>
<td>Improved sleep efficiency</td>
</tr>
<tr>
<td class="label">Quality of life</td>
<td>Statistically significant improvement</td>
</tr>
<tr>
<td class="label">Acupoint</td>
<td>Location</td>
</tr>
<tr>
<td class="label">LV3 (Taichong)</td>
<td>Between 1st/2nd toes</td>
</tr>
<tr>
<td class="label">GB20 (Fengchi)</td>
<td>Base of skull</td>
</tr>
<tr>
<td class="label">ST36 (Zusanli)</td>
<td>Below knee</td>
</tr>
<tr>
<td class="label">SP6 (Sanyinjiao)</td>
<td>Above ankle</td>
</tr>
<tr>
<td class="label">PC6 (Neiguan)</td>
<td>Wrist</td>
</tr>
<tr>
<td class="label">DU20 (Baihui)</td>
<td>Top of head</td>
</tr>
<tr>
<td class="label">LI4 (Hegu)</td>
<td>Hand</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Finding</td>
</tr>
<tr>
<td class="label">Muscle rigidity</td>
<td>Moderate reduction in tone</td>
</tr>
<tr>
<td class="label">Pain</td>
<td>Significant reduction</td>
</tr>
<tr>
<td class="label">Anxiety/depression</td>
<td>Improved mood scores</td>
</tr>
<tr>
<td class="label">Sleep quality</td>
<td>Improved sleep efficiency</td>
</tr>
<tr>
<td class="label">Technique</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Swedish Massage</td>
<td>Long strokes, gentle pressure</td>
</tr>
<tr>
<td class="label">Myofascial Release</td>
<td>Deep pressure to fascia</td>
</tr>
<tr>
<td class="label">Trigger Point</td>
<td>Direct pressure on tender points</td>
</tr>
<tr>
<td class="label">Gentle Stretching</td>
<td>Passive range of motion</td>
</tr>
<tr>
<td class="label">Reflexology</td>
<td>Pressure to feet/hands</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Finding</td>
</tr>
<tr>
<td class="label">Anxiety</td>
<td>Significant reduction (30-40%)</td>
</tr>
<tr>
<td class="label">Sleep quality</td>
<td>Improved sleep onset and duration</td>
</tr>
<tr>
<td class="label">Nausea</td>
<td>Reduction in chemotherapy-induced nausea</td>
</tr>
<tr>
<td class="label">Depression</td>
<td>Mild improvement</td>
</tr>
<tr>
<td class="label">Oil</td>
<td>Primary Use</td>
</tr>
<tr>
<td class="label">Lavender</td>
<td>Anxiety, sleep</td>
</tr>
<tr>
<td class="label">Bergamot</td>
<td>Anxiety, mood</td>
</tr>
<tr>
<td class="label">Chamomile</td>
<td>Sleep, anxiety</td>
</tr>
<tr>
<td class="label">Peppermint</td>
<td>Nausea, fatigue</td>
</tr>
<tr>
<td class="label">Rosemary</td>
<td>Cognitive support, fatigue</td>
</tr>
<tr>
<td class="label">Ylang Ylang</td>
<td>Anxiety, blood pressure</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Finding</td>
</tr>
<tr>
<td class="label">Gait/balance</td>
<td>Improved stride length, velocity</td>
</tr>
<tr>
<td class="label">Motor timing</td>
<td>Rhythmic auditory stimulation improves movement</td>
</tr>
<tr>
<td class="label">Depression/anxiety</td>
<td>Significant reduction</td>
</tr>
<tr>
<td class="label">Cognition</td>
<td>Improved verbal fluency</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Rhythmic Auditory Stimulation (RAS)</td>
<td>Rhythmic cues to improve gait timing</td>
</tr>
<tr>
<td class="label">Active Music Making</td>
<td>Playing instruments, singing</td>
</tr>
<tr>
<td class="label">Receptive Music Therapy</td>
<td>Listening to music</td>
</tr>
<tr>
<td class="label">Musical Gait Training</td>
<td>Music with metronome for walking</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Finding</td>
</tr>
<tr>
<td class="label">Anxiety</td>
<td>Significant reduction</td>
</tr>
<tr>
<td class="label">Depression</td>
<td>Moderate reduction</td>
</tr>
<tr>
<td class="label">Pain perception</td>
<td>Reduced pain catastrophizing</td>
</tr>
<tr>
<td class="label">Sleep</td>
<td>Improved sleep quality</td>
</tr>
<tr>
<td class="label">Cognition</td>
<td>Mild improvement in attention</td>
</tr>
<tr>
<td class="label">Technique</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Mindfulness-Based Stress Reduction (MBSR)</td>
<td>8-week structured program</td>
</tr>
<tr>
<td class="label">Body Scan</td>
<td>Systematic attention to body sensations</td>
</tr>
<tr>
<td class="label">Loving-Kindness (Metta)</td>
<td>Cultivate compassion for self/others</td>
</tr>
<tr>
<td class="label">Breath Awareness</td>
<td>Focus on breathing</td>
</tr>
<tr>
<td class="label">Guided Meditation</td>
<td>Led by instructor/recording</td>
</tr>
<tr>
<td class="label">Resource</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Insight Timer</td>
<td>App</td>
</tr>
<tr>
<td class="label">Mindfulness-Based Stress Reduction</td>
<td>Course</td>
</tr>
<tr>
<td class="label">Parkinson's Foundation Resources</td>
<td>Website</td>
</tr>
<tr>
<td class="label">Headspace</td>
<td>App</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Finding</td>
</tr>
<tr>
<td class="label">Pain</td>
<td>Moderate reduction</td>
</tr>
<tr>
<td class="label">Anxiety</td>
<td>Significant reduction</td>
</tr>
<tr>
<td class="label">Sleep</td>
<td>Improved sleep quality</td>
</tr>
<tr>
<td class="label">Chemotherapy side effects</td>
<td>Reduced nausea, fatigue</td>
</tr>
<tr>
<td class="label">Technique</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Progressive Relaxation</td>
<td>Image muscle groups relaxing</td>
</tr>
<tr>
<td class="label">Nature Scenes</td>
<td>Imagine peaceful environments</td>
</tr>
<tr>
<td class="label">Body Repair Imagery</td>
<td>Visualize healing processes</td>
</tr>
<tr>
<td class="label">Motor Imagory</td>
<td>Visualize movements</td>
</tr>
<tr>
<td class="label">Pain Control</td>
<td>Imagine pain as manageable</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Finding</td>
</tr>
<tr>
<td class="label">Balance</td>
<td>Significant improvement</td>
</tr>
<tr>
<td class="label">Flexibility</td>
<td>Improved range of motion</td>
</tr>
<tr>
<td class="label">Depression/anxiety</td>
<td>Moderate reduction</td>
</tr>
<tr>
<td class="label">Quality of life</td>
<td>Improved</td>
</tr>
<tr>
<td class="label">Gait</td>
<td>Mild improvement in velocity</td>
</tr>
<tr>
<td class="label">Style</td>
<td>Suitability</td>
</tr>
<tr>
<td class="label">Chair Yoga</td>
<td>Excellent</td>
</tr>
<tr>
<td class="label">Gentle/Restorative</td>
<td>Excellent</td>
</tr>
<tr>
<td class="label">Hatha (modified)</td>
<td>Good</td>
</tr>
<tr>
<td class="label">Iyengar</td>
<td>Good</td>
</tr>
<tr>
<td class="label">Kundalini</td>
<td>Caution</td>
</tr>
<tr>
<td class="label">Power/Vinyasa</td>
<td>Avoid</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Evidence Level</td>
</tr>
<tr>
<td class="label">Acupuncture</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Massage Therapy</td>
<td>Moderate-High</td>
</tr>
<tr>
<td class="label">Aromatherapy</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="label">Music Therapy</td>
<td>Moderate-High</td>
</tr>
<tr>
<td class="label">Meditation/Mindfulness</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Guided Imagery</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Adapted Yoga</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Day</td>
<td>Morning</td>
</tr>
<tr>
<td class="label">Monday</td>
<td>Gentle stretch/yoga</td>
</tr>
<tr>
<td class="label">Tuesday</td>
<td>Music therapy/rhythm</td>
</tr>
<tr>
<td class="label">Wednesday</td>
<td>Massage (weekly)</td>
</tr>
<tr>
<td class="label">Thursday</td>
<td>Acupuncture</td>
</tr>
<tr>
<td class="label">Friday</td>
<td>Music therapy</td>
</tr>
<tr>
<td class="label">Saturday</td>
<td>Gentle movement</td>
</tr>
<tr>
<td class="label">Sunday</td>
<td>Rest</td>
</tr>
<tr>
<td class="label">Resource</td>
<td>URL</td>
</tr>
<tr>
<td class="label">ClinicalTrials.gov</td>
<td>https://clinicaltrials.gov</td>
</tr>
<tr>
<td class="label">CurePSP Clinical Trials</td>
<td>https://www.curepsp.org/clinical-trials</td>
</tr>
<tr>
<td class="label">Michael J. Fox Foundation</td>
<td>https://www.michaeljfox.org/trial-finder</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Drug/Intervention</td>
</tr>
<tr>
<td class="label">~~NCT05615614~~</td>
<td>E2814 (Anti-tau)</td>
</tr>
<tr>
<td class="label">NCT05318985</td>
<td>Bepranemab</td>
</tr>
<tr>
<td class="label">NCT05297202</td>
<td>Lithium carbonate</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Test Frequency</td>
</tr>
<tr>
<td class="label">NfL (Neurofilament Light Chain)</td>
<td>Every 6 months</td>
</tr>
<tr>
<td class="label">p-tau217</td>
<td>Every 12 months</td>
</tr>
<tr>
<td class="label">GFAP</td>
<td>Every 12 months</td>
</tr>
<tr>
<td class="label">Modality</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">MRI with volumetrics</td>
<td>Every 12-24 months</td>
</tr>
<tr>
<td class="label">Tau PET (flortaucipir)</td>
<td>Baseline + 12-24 months</td>
</tr>
<tr>
<td class="label">DAT-SPECT</td>
<td>Every 24 months</td>
</tr>
<tr>
<td class="label">Device/Platform</td>
<td>Parameters</td>
</tr>
<tr>
<td class="label">Apple Watch / Samsung Watch</td>
<td>Step count, gait rhythm, tremor</td>
</tr>
<tr>
<td class="label">KinetiGait</td>
<td>Gait velocity, stride length</td>
</tr>
<tr>
<td class="label">PDMapper</td>
<td>Motor fluctuations, dyskinesia</td>
</tr>
<tr>
<td class="label">Verily Study Watch</td>
<td>Tremor, bradykinesia</td>
</tr>
<tr>
<td class="label">App</td>
<td>Assessment</td>
</tr>
<tr>
<td class="label">CogniFit</td>
<td>Executive function, memory</td>
</tr>
<tr>
<td class="label">BrainHQ</td>
<td>Cognitive training + metrics</td>
</tr>
<tr>
<td class="label">MyCognition</td>
<td>Working memory, attention</td>
</tr>
<tr>
<td class="label">Cambridge Neuropsychological Test Automated Battery (CANTAB)</td>
<td>Comprehensive cognitive battery</td>
</tr>
<tr>
<td class="label">Test</td>
<td>Baseline</td>
</tr>
<tr>
<td class="label">NfL blood</td>
<td>✓</td>
</tr>
<tr>
<td class="label">p-tau217</td>
<td>✓</td>
</tr>
<tr>
<td class="label">MRI volumetrics</td>
<td>✓</td>
</tr>
<tr>
<td class="label">Tau PET</td>
<td>✓</td>
</tr>
<tr>
<td class="label">Cognitive testing</td>
<td>✓</td>
</tr>
<tr>
<td class="label">Wearable monitoring</td>
<td>Continuous</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Reference Range</td>
</tr>
<tr>
<td class="label">Total tau</td>
<td><300 pg/mL</td>
</tr>
<tr>
<td class="label">p-tau181</td>
<td><50 pg/mL</td>
</tr>
<tr>
<td class="label">p-tau217</td>
<td><100 pg/mL</td>
</tr>
<tr>
<td class="label">NfL</td>
<td><800 pg/mL</td>
</tr>
<tr>
<td class="label">GFAP</td>
<td><200 pg/mL</td>
</tr>
<tr>
<td class="label">Alpha-synuclein RT-QuIC</td>
<td>Negative</td>
</tr>
<tr>
<td class="label">Tracer</td>
<td>Brand Name</td>
</tr>
<tr>
<td class="label">Flortaucipir (AV-1451)</td>
<td>Tauvid</td>
</tr>
<tr>
<td class="label">MK-6240</td>
<td>—</td>
</tr>
<tr>
<td class="label">PI-2620</td>
<td>—</td>
</tr>
<tr>
<td class="label">Finding</td>
<td>CBS</td>
</tr>
<tr>
<td class="label">Asymmetric cortical uptake</td>
<td>Common (>70%)</td>
</tr>
<tr>
<td class="label">Midbrain/brainstem uptake</td>
<td>Rare</td>
</tr>
<tr>
<td class="label">Putamen uptake</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Cerebellar uptake</td>
<td>Rare</td>
</tr>
<tr>
<td class="label">Center</td>
<td>Location</td>
</tr>
<tr>
<td class="label">UCSF</td>
<td>San Francisco</td>
</tr>
<tr>
<td class="label">Mayo Clinic</td>
<td>Rochester</td>
</tr>
<tr>
<td class="label">MGH</td>
<td>Boston</td>
</tr>
<tr>
<td class="label">Cleveland Clinic</td>
<td>Cleveland</td>
</tr>
<tr>
<td class="label">Organization</td>
<td>Services</td>
</tr>
<tr>
<td class="label">CurePSP</td>
<td>Education, support groups, care navigator, research advocacy</td>
</tr>
<tr>
<td class="label">Michael J. Fox Foundation</td>
<td>Research updates, clinical trial matching, support programs</td>
</tr>
<tr>
<td class="label">Parkinson's Foundation</td>
<td>Helpline, support groups, caregiving resources</td>
</tr>
<tr>
<td class="label">AFTD (Association for Frontotemporal Degeneration)</td>
<td>Support groups, education, caregiver resources</td>
</tr>
<tr>
<td class="label">Family Caregiver Alliance</td>
<td>Comprehensive caregiver resources, policy advocacy</td>
</tr>
<tr>
<td class="label">Caregiver Action Network</td>
<td>Peer support, resources, family caregiving tips</td>
</tr>
<tr>
<td class="label">Brain Support Network</td>
<td>Patient/family support, resource navigation</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Assessment</td>
</tr>
<tr>
<td class="label">Relevance</td>
<td>10/10</td>
</tr>
<tr>
<td class="label">Urgency</td>
<td>High</td>
</tr>
<tr>
<td class="label">Resource Availability</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Implementation Complexity</td>
<td>Low-Medium</td>
</tr>
<tr>
<td class="label">Overall Priority</td>
<td>Essential</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Fludrocortisone</td>
<td>0.1-0.2 mg/day</td>
</tr>
<tr>
<td class="label">Midodrine</td>
<td>5-10 mg TID</td>
</tr>
<tr>
<td class="label">Droxidopa</td>
<td>100-600 mg TID</td>
</tr>
<tr>
<td class="label">Pyridostigmine</td>
<td>60 mg TID</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Fiber supplementation</td>
<td>25-35 g/day</td>
</tr>
<tr>
<td class="label">Polyethylene glycol (Miralax)</td>
<td>17 g/day</td>
</tr>
<tr>
<td class="label">Sennosides</td>
<td>8.6-17.2 mg PRN</td>
</tr>
<tr>
<td class="label">Lubiprostone</td>
<td>8-24 μg BID</td>
</tr>
<tr>
<td class="label">Linaclotide</td>
<td>145-290 μg QD</td>
</tr>
<tr>
<td class="label">Prucalopride</td>
<td>2 mg QD</td>
</tr>
<tr>
<td class="label">Metoclopramide</td>
<td>10 mg TID</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Oxybutynin</td>
<td>2.5-5 mg BID-TID</td>
</tr>
<tr>
<td class="label">Tolterodine</td>
<td>2-4 mg BID</td>
</tr>
<tr>
<td class="label">Solifenacin</td>
<td>5-10 mg QD</td>
</tr>
<tr>
<td class="label">Trospium</td>
<td>20 mg BID</td>
</tr>
<tr>
<td class="label">Mirabegron</td>
<td>25-50 mg QD</td>
</tr>
<tr>
<td class="label">Treatment</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Sildenafil</td>
<td>25-100 mg PRN</td>
</tr>
<tr>
<td class="label">Tadalafil</td>
<td>5-20 mg PRN/QD</td>
</tr>
<tr>
<td class="label">Vardenafil</td>
<td>5-20 mg PRN</td>
</tr>
<tr>
<td class="label">Test</td>
<td>Purpose</td>
</tr>
<tr>
<td class="label">Tilt-table test</td>
<td>Confirm orthostatic hypotension</td>
</tr>
<tr>
<td class="label">Bladder ultrasound</td>
<td>Post-void residual volume</td>
</tr>
<tr>
<td class="label">Urodynamic studies</td>
<td>Detailed bladder function</td>
</tr>
<tr>
<td class="label">Cardiac MIBG scan</td>
<td>Differentiate synucleinopathies</td>
</tr>
<tr>
<td class="label">Skin biopsy</td>
<td>Autonomic nerve fiber density</td>
</tr>
<tr>
<td class="label">Drug Category</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Antimuscarinics</td>
<td>May reduce GI motility, affect levodopa absorption</td>
</tr>
<tr>
<td class="label">α1-blockers (tamsulosin)</td>
<td>Additive hypotension, especially with midodrine</td>
</tr>
<tr>
<td class="label">PDE5 inhibitors</td>
<td>Additive hypotension with vasodilators</td>
</tr>
<tr>
<td class="label">Sympathomimetics (midodrine)</td>
<td>MAO-Bi interaction risk</td>
</tr>
<tr>
<td class="label">Metoclopramide</td>
<td>May worsen parkinsonism</td>
</tr>
<tr>
<td class="label">SSRIs</td>
<td>Serotonin syndrome risk with MAO-Bi (theoretical)</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Assessment</td>
</tr>
<tr>
<td class="label">Mechanism fit</td>
<td>High — autonomic dysfunction is a core feature of atypical parkinsonism</td>
</tr>
<tr>
<td class="label">Evidence level</td>
<td>High — established symptom management algorithms</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>Generally good with appropriate monitoring</td>
</tr>
<tr>
<td class="label">Accessibility</td>
<td>High — all interventions available and most are off-patent</td>
</tr>
<tr>
<td class="label">Priority</td>
<td>HIGH — quality of life impact is substantial</td>
</tr>
<tr>
<td class="label">Cost</td>
<td>Typically Covered By</td>
</tr>
<tr>
<td class="label">Study drug</td>
<td>Sponsor 100%</td>
</tr>
<tr>
<td class="label">Study visits</td>
<td>Sponsor 100%</td>
</tr>
<tr>
<td class="label">Procedures</td>
<td>Sponsor 100%</td>
</tr>
<tr>
<td class="label">Travel</td>
<td>Some sponsors offer stipends</td>
</tr>
<tr>
<td class="label">Item</td>
<td>Annual Cost</td>
</tr>
<tr>
<td class="label">Levodopa</td>
<td>$500-2,000</td>
</tr>
<tr>
<td class="label">CoQ10</td>
<td>$300-600</td>
</tr>
<tr>
<td class="label">NACET</td>
<td>$300-500</td>
</tr>
<tr>
<td class="label">Tau PET</td>
<td>$10,000-15,000</td>
</tr>
<tr>
<td class="label">Medication</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Fludrocortisone</td>
<td>0.1-0.3mg daily</td>
</tr>
<tr>
<td class="label">Midodrine</td>
<td>5-10mg TID</td>
</tr>
<tr>
<td class="label">Droxidopa</td>
<td>100-600mg TID</td>
</tr>
<tr>
<td class="label">Pyridostigmine</td>
<td>60-120mg daily</td>
</tr>
<tr>
<td class="label">Medication</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Polyethylene glycol</td>
<td>17g daily</td>
</tr>
<tr>
<td class="label">Lactulose</td>
<td>15-30ml BID</td>
</tr>
<tr>
<td class="label">Senna</td>
<td>8.6-17.2mg daily</td>
</tr>
<tr>
<td class="label">Docusate</td>
<td>100mg BID</td>
</tr>
<tr>
<td class="label">Accommodation</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Flexible schedule</td>
<td>Work around medication "on" times</td>
</tr>
<tr>
<td class="label">Modified duties</td>
<td>Reduce physical demands</td>
</tr>
<tr>
<td class="label">Assistive technology</td>
<td>Voice recognition, ergonomic equipment</td>
</tr>
<tr>
<td class="label">Rest periods</td>
<td>Frequent breaks for fatigue</td>
</tr>
<tr>
<td class="label">Remote work</td>
<td>Reduce commuting stress</td>
</tr>
<tr>
<td class="label">Job coaching</td>
<td>On-site support for accommodations</td>
</tr>
<tr>
<td class="label">Step</td>
<td>Description</td>
</tr>
<tr>
<td class="label">1. Gather records</td>
<td>Medical records, work history, financial documents</td>
</tr>
<tr>
<td class="label">2. Complete application</td>
<td>Online at ssa.gov or in person</td>
</tr>
<tr>
<td class="label">3. Submit evidence</td>
<td>Diagnosis, treatment records, functional assessments</td>
</tr>
<tr>
<td class="label">4. Decision</td>
<td>Initial decision on claim</td>
</tr>
<tr>
<td class="label">Option</td>
<td>Pros</td>
</tr>
<tr>
<td class="label">Same employer, modified role</td>
<td>Familiar environment, benefits</td>
</tr>
<tr>
<td class="label">New employer, similar role</td>
<td>Fresh start, may have accommodations</td>
</tr>
<tr>
<td class="label">Career change</td>
<td>Leverage transferable skills</td>
</tr>
<tr>
<td class="label">Self-employment</td>
<td>Flexibility, control</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Early (no significant impairment)</td>
<td>May drive with caution; annual assessment</td>
</tr>
<tr>
<td class="label">Moderate (motor/cognitive changes)</td>
<td>Restrict to familiar routes; consider driving cessation</td>
</tr>
<tr>
<td class="label">Advanced</td>
<td>Recommend cessation; explore transportation alternatives</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Relevance</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Accessibility</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Evidence base</td>
<td>6/10</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>10/10</td>
</tr>
<tr>
<td class="label">Overall priority</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Food Category</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">Berries</td>
<td>Blueberries, strawberries</td>
</tr>
<tr>
<td class="label">Leafy greens</td>
<td>Spinach, kale</td>
</tr>
<tr>
<td class="label">Nuts</td>
<td>Walnuts, almonds</td>
</tr>
<tr>
<td class="label">Fatty fish</td>
<td>Salmon, mackerel</td>
</tr>
<tr>
<td class="label">Whole grains</td>
<td>Oats, quinoa</td>
</tr>
<tr>
<td class="label">Legumes</td>
<td>Black beans, lentils</td>
</tr>
<tr>
<td class="label">Olive oil</td>
<td>Extra virgin</td>
</tr>
<tr>
<td class="label">Coffee/tea</td>
<td>Moderate caffeine</td>
</tr>
<tr>
<td class="label">Category</td>
<td>Signs</td>
</tr>
<tr>
<td class="label">Physical</td>
<td>Chronic fatigue, sleep disturbances, frequent illness, changes in appetite</td>
</tr>
<tr>
<td class="label">Emotional</td>
<td>Irritability, hopelessness, anxiety, feeling trapped</td>
</tr>
<tr>
<td class="label">Behavioral</td>
<td>Social withdrawal, neglect of own health, increased alcohol use</td>
</tr>
<tr>
<td class="label">Cognitive</td>
<td>Difficulty concentrating, memory problems, making errors</td>
</tr>
<tr>
<td class="label">Community</td>
<td>Platform</td>
</tr>
<tr>
<td class="label">Reddit r/Parkinsons</td>
<td>Reddit</td>
</tr>
<tr>
<td class="label">PatientsLikeMe</td>
<td>Online forum</td>
</tr>
<tr>
<td class="label">Facebook CBS/PSP groups</td>
<td>Facebook</td>
</tr>
<tr>
<td class="label">MyParkinsons</td>
<td>Online</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Description</td>
</tr>
<tr>
<td class="label">In-home aide</td>
<td>Professional caregiver comes to home</td>
</tr>
<tr>
<td class="label">Adult day care</td>
<td>Day program at facility</td>
</tr>
<tr>
<td class="label">Short-term facility</td>
<td>Nursing home or assisted living</td>
</tr>
<tr>
<td class="label">Family/friends</td>
<td>Relief from trusted individuals</td>
</tr>
<tr>
<td class="label">Document</td>
<td>Purpose</td>
</tr>
<tr>
<td class="label">Advance Directive</td>
<td>Documents care preferences</td>
</tr>
<tr>
<td class="label">Healthcare Proxy</td>
<td>Names decision-maker</td>
</tr>
<tr>
<td class="label">POLST/MOLST</td>
<td>Emergency care preferences</td>
</tr>
<tr>
<td class="label">DNR Order</td>
<td>Do-not-resuscitate</td>
</tr>
<tr>
<td class="label">Document</td>
<td>Purpose</td>
</tr>
<tr>
<td class="label">Power of Attorney (POA)</td>
<td>Authorizes financial decisions</td>
</tr>
<tr>
<td class="label">Healthcare Proxy</td>
<td>Authorizes medical decisions</td>
</tr>
<tr>
<td class="label">Will</td>
<td>Distributes assets</td>
</tr>
<tr>
<td class="label">Trust</td>
<td>Manages assets, may avoid probate</td>
</tr>
<tr>
<td class="label">Source</td>
<td>Coverage</td>
</tr>
<tr>
<td class="label">Medicare</td>
<td>Limited home health (must be "homebound" with skilled need)</td>
</tr>
<tr>
<td class="label">Medicaid</td>
<td>May cover personal care services</td>
</tr>
<tr>
<td class="label">Long-term care insurance</td>
<td>Varies by policy</td>
</tr>
<tr>
<td class="label">Private pay</td>
<td>$20-40/hour depending on location</td>
</tr>
<tr>
<td class="label">Action</td>
<td>Priority</td>
</tr>
<tr>
<td class="label">Identify local support groups (PD, CurePSP)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Schedule legal consultation for advance directives</td>
<td>High</td>
</tr>
<tr>
<td class="label">Explore respite care options</td>
<td>Medium</td>
</tr>
<tr>
<td class="label">Apply for disability benefits if applicable</td>
<td>High</td>
</tr>
<tr>
<td class="label">Discuss palliative care with neurologist</td>
<td>Medium</td>
</tr>
<tr>
<td class="label">Consider home health aide for assistance</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Join online caregiver community</td>
<td>Medium</td>
</tr>
<tr>
<td class="label">Resource</td>
<td>Contact</td>
</tr>
<tr>
<td class="label">CurePSP</td>
<td>curepsp.org, 1-866-457-4276</td>
</tr>
<tr>
<td class="label">Parkinson's Foundation</td>
<td>parkinson.org</td>
</tr>
<tr>
<td class="label">Family Caregiver Alliance</td>
<td>caregiver.org</td>
</tr>
<tr>
<td class="label">AARP Caregiving</td>
<td>aarp.org/caregiving</td>
</tr>
<tr>
<td class="label">Area Agency on Aging</td>
<td>n4a.org</td>
</tr>
<tr>
<td class="label">Social Security Administration</td>
<td>ssa.gov</td>
</tr>
<tr>
<td class="label">The Conversation Project</td>
<td>theconversationproject.org</td>
</tr>
<tr>
<td class="label">Medicare</td>
<td>medicare.gov</td>
</tr>
<tr>
<td class="label">Sleep Disorder</td>
<td>Prevalence in CBS/PSP</td>
</tr>
<tr>
<td class="label">REM Sleep Behavior Disorder (RBD)</td>
<td>20-30%</td>
</tr>
<tr>
<td class="label">Insomnia</td>
<td>40-60%</td>
</tr>
<tr>
<td class="label">Sleep Apnea</td>
<td>30-50%</td>
</tr>
<tr>
<td class="label">Restless Legs Syndrome (RLS)</td>
<td>15-25%</td>
</tr>
<tr>
<td class="label">Excessive Daytime Sleepiness (EDS)</td>
<td>30-40%</td>
</tr>
<tr>
<td class="label">Circadian Rhythm Disorders</td>
<td>20-35%</td>
</tr>
<tr>
<td class="label">Tool</td>
<td>Purpose</td>
</tr>
<tr>
<td class="label">Videopolysomnography (vPSG)</td>
<td>Gold standard for RBD diagnosis</td>
</tr>
<tr>
<td class="label">RBD Screening Questionnaire (RBD-Q)</td>
<td>Clinical screening</td>
</tr>
<tr>
<td class="label">Mayo Sleep Questionnaire</td>
<td>Collateral history</td>
</tr>
<tr>
<td class="label">Single-Photon Emission CT</td>
<td>Differentiation</td>
</tr>
<tr>
<td class="label">Medication</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Melatonin</td>
<td>3-12 mg HS</td>
</tr>
<tr>
<td class="label">Clonazepam</td>
<td>0.25-1.0 mg HS</td>
</tr>
<tr>
<td class="label">Pramipexole</td>
<td>0.125-0.5 mg HS</td>
</tr>
<tr>
<td class="label">Subtype</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Sleep Onset Insomnia</td>
<td>Hyperarousal, levodopa effects</td>
</tr>
<tr>
<td class="label">Sleep Maintenance Insomnia</td>
<td>Nocturnal akinesia, RBD, pain</td>
</tr>
<tr>
<td class="label">Terminal Insomnia</td>
<td>Early morning awakening, depression</td>
</tr>
<tr>
<td class="label">Medication</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Melatonin</td>
<td>1-10 mg</td>
</tr>
<tr>
<td class="label">Trazodone</td>
<td>25-100 mg</td>
</tr>
<tr>
<td class="label">Mirtazapine</td>
<td>7.5-15 mg</td>
</tr>
<tr>
<td class="label">Gabapentin</td>
<td>100-600 mg</td>
</tr>
<tr>
<td class="label">Quetiapine</td>
<td>12.5-50 mg</td>
</tr>
<tr>
<td class="label">Test</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Home Sleep Apnea Test</td>
<td>High pre-test probability</td>
</tr>
<tr>
<td class="label">Polysomnography</td>
<td>Diagnostic uncertainty, comorbid conditions</td>
</tr>
<tr>
<td class="label">Arterial Blood Gas</td>
<td>Suspected hypoventilation</td>
</tr>
<tr>
<td class="label">Treatment</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">CPAP</td>
<td>Moderate-severe OSA</td>
</tr>
<tr>
<td class="label">APAP</td>
<td>Variable breathing patterns</td>
</tr>
<tr>
<td class="label">BiPAP</td>
<td>Central apnea, complex OSA</td>
</tr>
<tr>
<td class="label">Weight Management</td>
<td>Obesity-related OSA</td>
</tr>
<tr>
<td class="label">Positional Therapy</td>
<td>Positional OSA</td>
</tr>
<tr>
<td class="label">Surgical</td>
<td>Anatomic obstruction</td>
</tr>
<tr>
<td class="label">Medication</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Pramipexole</td>
<td>0.125-0.5 mg</td>
</tr>
<tr>
<td class="label">Rotigotine patch</td>
<td>0.5-3 mg/24h</td>
</tr>
<tr>
<td class="label">Gabapentin</td>
<td>300-900 mg</td>
</tr>
<tr>
<td class="label">Pregabalin</td>
<td>75-300 mg</td>
</tr>
<tr>
<td class="label">Iron supplementation</td>
<td>If ferritin <75 ng/mL</td>
</tr>
<tr>
<td class="label">Test</td>
<td>Purpose</td>
</tr>
<tr>
<td class="label">Epworth Sleepiness Scale</td>
<td>Quantify sleepiness severity</td>
</tr>
<tr>
<td class="label">Polysomnography</td>
<td>Evaluate nocturnal sleep quality</td>
</tr>
<tr>
<td class="label">MSLT</td>
<td>Objective sleepiness, rule out narcolepsy</td>
</tr>
<tr>
<td class="label">Multiple Sleep Latency Test</td>
<td>Assess sleep latency, sleep onset REM periods</td>
</tr>
<tr>
<td class="label">Medication</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Modafinil</td>
<td>100-400 mg</td>
</tr>
<tr>
<td class="label">Armodafinil</td>
<td>50-250 mg</td>
</tr>
<tr>
<td class="label">Methylphenidate</td>
<td>5-20 mg</td>
</tr>
<tr>
<td class="label">Caffeine</td>
<td>100-200 mg</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Characteristics</td>
</tr>
<tr>
<td class="label">Advanced Sleep Phase</td>
<td>Early bedtime, early waking</td>
</tr>
<tr>
<td class="label">Irregular Sleep-Wake</td>
<td>No consistent pattern</td>
</tr>
<tr>
<td class="label">Non-24-Hour</td>
<td>Progressive delay</td>
</tr>
<tr>
<td class="label">Fragmented Sleep</td>
<td>Frequent awakenings</td>
</tr>
<tr>
<td class="label">Sleep Medication</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Clonazepam</td>
<td>Additive CNS depression, falls</td>
</tr>
<tr>
<td class="label">Melatonin</td>
<td>May enhance sedative effect</td>
</tr>
<tr>
<td class="label">Trazodone</td>
<td>Additive sedation</td>
</tr>
<tr>
<td class="label">Mirtazapine</td>
<td>May worsen RBD</td>
</tr>
<tr>
<td class="label">Modafinil</td>
<td>May affect cytochrome metabolism</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Rating</td>
</tr>
<tr>
<td class="label">Mechanistic Rationale</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Accessibility</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Priority</td>
<td>High</td>
</tr>
<tr>
<td class="label">Instrument</td>
<td>Domain Assessed</td>
</tr>
<tr>
<td class="label">MDS-UPDRS</td>
<td>Motor + non-motor</td>
</tr>
<tr>
<td class="label">PDQ-39</td>
<td>Quality of life</td>
</tr>
<tr>
<td class="label">NMSQ</td>
<td>Non-motor symptoms</td>
</tr>
<tr>
<td class="label">FAB</td>
<td>Frontal lobe function</td>
</tr>
<tr>
<td class="label">SCOPA-PC</td>
<td>Psychosocial</td>
</tr>
<tr>
<td class="label">PDSS</td>
<td>Sleep quality</td>
</tr>
<tr>
<td class="label">MFI-20</td>
<td>Fatigue</td>
</tr>
<tr>
<td class="label">Instrument</td>
<td>Domain</td>
</tr>
<tr>
<td class="label">PSPRS</td>
<td>PSP rating scale</td>
</tr>
<tr>
<td class="label">CBRS</td>
<td>CBS rating scale</td>
</tr>
<tr>
<td class="label">CBS-MoCA</td>
<td>Cognitive screening</td>
</tr>
<tr>
<td class="label">CBI</td>
<td>Caregiver burden</td>
</tr>
<tr>
<td class="label">Instrument</td>
<td>Domain</td>
</tr>
<tr>
<td class="label">SF-36</td>
<td>Physical/mental health</td>
</tr>
<tr>
<td class="label">EQ-5D-5L</td>
<td>Health utility</td>
</tr>
<tr>
<td class="label">PROMIS Pain</td>
<td>Pain impact</td>
</tr>
<tr>
<td class="label">PROMIS Fatigue</td>
<td>Fatigue</td>
</tr>
<tr>
<td class="label">GDS</td>
<td>Depression</td>
</tr>
<tr>
<td class="label">GAI</td>
<td>Anxiety</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Key Concerns</td>
</tr>
<tr>
<td class="label">Physical function</td>
<td>Gait impairment, tremor, falls</td>
</tr>
<tr>
<td class="label">Social function</td>
<td>Isolation, communication difficulty</td>
</tr>
<tr>
<td class="label">Psychological</td>
<td>Depression, anxiety, apathy</td>
</tr>
<tr>
<td class="label">Cognition</td>
<td>Executive dysfunction, apraxia</td>
</tr>
<tr>
<td class="label">ADL independence</td>
<td>Dressing, eating, hygiene</td>
</tr>
<tr>
<td class="label">Pain</td>
<td>Musculoskeletal, dystonic</td>
</tr>
<tr>
<td class="label">Fatigue</td>
<td>Persistent exhaustion</td>
</tr>
<tr>
<td class="label">Sleep</td>
<td>Insomnia, RBD</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Primary QoL Impact</td>
</tr>
<tr>
<td class="label">Early (1-2 years)</td>
<td>Anxiety about diagnosis, mild ADL difficulties</td>
</tr>
<tr>
<td class="label">Moderate (2-4 years)</td>
<td>Functional decline, social withdrawal</td>
</tr>
<tr>
<td class="label">Advanced (4+ years)</td>
<td>Major dependency, neuropsychiatric symptoms</td>
</tr>
<tr>
<td class="label">Tool</td>
<td>Domain</td>
</tr>
<tr>
<td class="label">Zarit Burden Interview</td>
<td>Caregiver strain</td>
</tr>
<tr>
<td class="label">Caregiver Burden Inventory</td>
<td>Multiple dimensions</td>
</tr>
<tr>
<td class="label">Bakas Caregiving Outcomes Scale</td>
<td>Life changes</td>
</tr>
<tr>
<td class="label">Caregiver Strain Index</td>
<td>Role strain</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>Evidence Level</td>
</tr>
<tr>
<td class="label">Caregiver support groups</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">Respite care</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Psychoeducation</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">Cognitive behavioral therapy</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Care coordination</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Treatment Goal</td>
<td>Patient Preference Considerations</td>
</tr>
<tr>
<td class="label">Motor symptom control</td>
<td>Prioritizes independence</td>
</tr>
<tr>
<td class="label">Cognitive preservation</td>
<td>Values mental function</td>
</tr>
<tr>
<td class="label">Disease modification</td>
<td>Wants aggressive approach</td>
</tr>
<tr>
<td class="label">Quality of life</td>
<td>Concerned about burden</td>
</tr>
<tr>
<td class="label">Life extension</td>
<td>Mixed priorities</td>
</tr>
<tr>
<td class="label">Timepoint</td>
<td>Assessments</td>
</tr>
<tr>
<td class="label">Baseline</td>
<td>Full PRO battery</td>
</tr>
<tr>
<td class="label">Month 3</td>
<td>MDS-UPDRS, PDQ-39, NMSQ</td>
</tr>
<tr>
<td class="label">Month 6</td>
<td>Full battery</td>
</tr>
<tr>
<td class="label">Month 12</td>
<td>Full battery + caregiver burden</td>
</tr>
<tr>
<td class="label">Every 6 months</td>
<td>Core battery</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Score</td>
</tr>
<tr>
<td class="label">PRO instrument validation for CBS/PSP</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Patient engagement in outcome assessment</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Caregiver involvement in assessment</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Integration into clinical care</td>
<td>6/10</td>
</tr>
<tr>
<td class="label">Electronic collection systems</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Longitudinal tracking protocols</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Medication</td>
<td>Effect on PRO</td>
</tr>
<tr>
<td class="label">Levodopa</td>
<td>May improve motor PROs initially</td>
</tr>
<tr>
<td class="label">Rasagiline</td>
<td>Minimal direct PRO effect</td>
</tr>
<tr>
<td class="label">Proposed supplements</td>
<td>Monitor fatigue, GI symptoms</td>
</tr>
</table>

Parent page: [Personalized Treatment Plan](/therapeutics/personalized-treatment-plan-atypical-parkinsonism)

28. Neuropsychiatric and Cognitive Management

Neuropsychiatric symptoms are common in atypical parkinsonism (CBS/PSP) and significantly impact quality of life. This section covers pharmacological and non-pharmacological approaches to manage cognitive decline, mood disorders, psychosis, and behavioral symptoms.

28.1 Cognitive Enhancers

Cognitive impairment in CBS/PSP involves executive dysfunction, apraxia, and visuospatial deficits. Standard AD medications have limited but relevant utility.

28.1.1 Cholinesterase Inhibitors

Evidence Summary:

Donepezil showed modest cognitive benefits in PSP in a 24-week RCT[^CE1]
Cholinesterase inhibitors may worsen parkinsonism in some patients — monitor closely
BuChE inhibition (rivastigmine) may be more relevant as BuChE activity increases with neurodegeneration

NET Assessment:

Consider donepezil 5-10mg daily if cognitive symptoms are prominent
Start low (5mg), titrate slowly
Monitor for GI side effects, bradycardia

28.1.2 Memantine

Evidence: A small crossover trial in PSP showed no cognitive benefit but some behavioral improvement[^CE2]

NET Assessment: Low priority — limited efficacy; may try if cholinesterase inhibitor not effective

28.2 Mood Stabilizers and Antidepressants

Depression and anxiety are common in CBS/PSP and require careful management given medication interactions.

28.2.1 SSRIs

Important: SSRIs have minimal interaction with levodopa/rasagiline. Avoid MAOIs (phenelzine, tranylcypromine) due to serotonin syndrome risk with MAO-B inhibitors.

28.2.2 Other Antidepressants

NET Assessment: Sertraline or venlafaxine are first-line for depression. Avoid tricyclics (amitriptyline) due to anticholinergic effects and confusion risk.

28.2.3 Mood Stabilizers

Note: Lithium requires careful monitoring (thyroid, kidney). May have neuroprotective properties relevant to tauopathy.

28.3 Antipsychotics for PD/PSP/CBS

Psychosis (hallucinations, delusions) is challenging — standard antipsychotics worsen parkinsonism. The following are dopamine D2-preserving options.

28.3.1 Pimavanserin (Nuplazid)

Evidence: CLARITY trial showed significant reduction in psychosis without worsening motor symptoms[^AP1]

Dosing: 34mg daily (start with 34mg, no titration needed)

NET Assessment: Strong recommendation — first-line for psychosis in PD/PD+ (may help CBS/PSP)

28.3.2 Quetiapine (Seroquel)

Dosing: 12.5-50mg nightly (start low, titrate as needed)

NET Assessment: Second-line if pimavanserin unavailable or ineffective

28.3.3 Clozapine (Clozaril)

Dosing: 6.25-50mg nightly (requires REMS program)

NET Assessment: Third-line — most effective but requires monitoring

28.3.4 What to AVOID

28.4 Sleep Medications

Sleep disturbances are common in CBS/PSP — RBD, insomnia, and fragmented sleep. Management requires careful medication selection.

28.4.1 Insomnia

28.4.2 REM Behavior Disorder (RBD)

RBD in CBS/PSP is typically treated with:

Important: Clonazepam (a benzodiazepine) should be used cautiously in elderly CBS/PSP patients due to fall risk and confusion. Melatonin is often preferred.

28.4.3 Excessive Daytime Sleepiness (EDS)

28.5 Anxiety Management

Anxiety in CBS/PSP may be secondary to neurodegeneration, medication effects, or reaction to diagnosis.

28.5.1 Non-Pharmacological

28.5.2 Pharmacological

NET Assessment: Prioritize non-pharmacological approaches. SSRIs for chronic anxiety.

28.6 Behavioral Interventions

Non-pharmacological approaches are critical for neuropsychiatric symptoms in CBS/PSP.

28.6.1 Cognitive Behavioral Therapy (CBT)

Effective for depression, anxiety, and adjustment disorder
Helps patient cope with diagnosis and functional decline
Available via telehealth

28.6.2 Occupational Therapy (OT)

Addresses functional independence
Environmental modifications
Fall prevention strategies

28.6.3 Speech Therapy

Address dysarthria, dysphagia
LSVT LOUD® for voice changes

28.6.4 Caregiver Support

Caring for someone with CBS or PSP presents unique challenges due to the progressive nature of these conditions, the cognitive and behavioral changes, and the complex care needs. Supporting caregivers is essential for maintaining quality of life for both patient and caregiver.

28.6.4.1 Caregiver Burnout

Caregiver burnout is a state of physical, emotional, and mental exhaustion that occurs when caregivers do not receive the help they need or try to do more than they are able.

Warning Signs:

Chronic fatigue, sleep disturbances
Irritability, anger, or resentment toward the patient
Neglecting own health and medical needs
Withdrawal from friends, family, and previously enjoyed activities
Feelings of hopelessness, depression, or anxiety
Increased use of alcohol or substances

Prevention Strategies:

Set realistic expectations about disease progression
Accept that you cannot provide all care alone
Maintain personal health routines (exercise, sleep, nutrition)
Stay connected with friends and support networks
Seek professional help when needed

28.6.4.2 Support Groups

CurePSP

Website: [curepsp.org](https://www.curepsp.org)
Phone: 1-800-457-4777
Services: Support groups (in-person and virtual), educational conferences, caregiver resources, peer mentorship
Focus: PSP, CBD, and related tauopathies

Parkinson's Foundation

Website: [parkinson.org](https://www.parkinson.org)
Helpline: 1-800-4PD-INFO (1-800-473-4636)
Services: Support groups, helpline, educational resources, movement disorder specialists directory
Note: Many PSP and CBS patients benefit from PD support groups as well

Online Communities:

[PatientsLikeMe](https://www.patientslikeme.com) — Connect with other CBS/PSP caregivers
[Reddit r/PSP](https://www.reddit.com/r/PSP/) — Peer support and advice
[Facebook Groups](https://www.facebook.com/groups) — CBS/PSP caregiver support groups

28.6.4.3 Respite Care Options

Respite care provides temporary relief for caregivers, allowing them to take breaks while ensuring their loved one receives proper care.

Finding Respite Services:

[ARCH National Respite Network](https://archrespite.org) — Respite locator
[CareLinx](https://www.carelinx.com) — In-home caregiver matching
Area Agency on Aging — Local respite programs
Veterans: [VA Respite Care](https://www.va.gov/geriatrics/) — For eligible veterans

Medicare/Medicaid:

Medicare may cover limited respite under certain conditions
Medicaid waiver programs often include respite benefits
Long-term care insurance may cover respite

28.6.4.4 Home Health Aides

Home health aides provide assistance with daily activities, complementing family caregiving.

Services Provided:

Personal care (bathing, dressing, grooming)
Medication reminders and monitoring
Light housekeeping and meal preparation
Transportation to medical appointments
Companionship and supervision
Assistance with mobility and transfers

How to Find Home Health Aides:

Home health agencies (licensed and bonded)
[Care.com](https://www.care.com) — Caregiver matching platform
[AARP Caregiver Resource Center](https://www.aarp.org/caregiving/) — Resource guides
Local-area agencies on aging

Cost Considerations:

Average cost: $25-35/hour
Medicare: May cover if patient meets homebound criteria
Medicaid: Often covers through waiver programs
Long-term care insurance: Check policy details

28.6.4.5 Legal and Financial Planning

Advance Directives

Power of Attorney (POA):

Healthcare POA: Designates someone to make medical decisions if the patient cannot
Financial POA: Designates someone to manage finances, bills, and assets
Dementia-specific POA: Include provisions for cognitive decline
Recommendation: Establish POAs early, while the patient can actively participate

Advance Healthcare Directive:

Specifies wishes for medical care if patient cannot communicate
Living will outlines preferences for life-sustaining treatment
Do Not Resuscitate (DNR) orders should be discussed

Resources:

[Legal Aid Society](https://www.lssny.org) — Free legal services for qualifying individuals
[EstateLawFirms.com](https://www.estatelawfirms.com) — Find elder law attorneys
[National Academy of Elder Law Attorneys](https://www.naela.org) — Specialist directory

Disability Benefits

Social Security Disability Insurance (SSDI):

Monthly benefit based on work history
5-month waiting period after disability onset
Coverage includes Medicare after 24 months
Apply at [ssa.gov](https://www.ssa.gov)

Supplemental Security Income (SSI):

For those with limited work history and financial need
Provides monthly cash benefit
Automatically qualifies for Medicaid

For Patients:

PSP and CBS qualify under Social Security's "Disorders of the Nervous System" (Listing 11.06)
Gather medical records documenting progressive symptoms
Consider hiring a disability attorney

For Caregivers:

Family and Medical Leave Act (FMLA): Up to 12 weeks unpaid leave per year
State caregiver programs: Vary by state; some offer stipends

Long-Term Care Planning

Long-term care insurance: Consider if patient is younger (premiums increase with age)
Veterans' benefits: [Aid and Attendance](https://www.va.gov/pension/aid-attendance-housebound/) provides additional monthly payment
Hybrid life/LTC policies: Combine life insurance with long-term care coverage
Pooled income trusts: For managing assets while qualifying for Medicaid

28.6.4.6 Caregiver Coping Strategies

Emotional Coping:

Acknowledge grief and loss — you are losing the person as they were
Join a caregiver support group (in-person or online)
Consider individual counseling or therapy
Practice self-compassion — this is hard work
Celebrate small victories and moments of connection

Practical Coping:

Use a caregiving notebook or app to track medications, appointments
Create a daily routine — structure provides predictability
Prepare simple meals in advance
Accept help when offered — make specific requests
Use adaptive equipment to make tasks easier

Building a Support System:

Identify family members who can help regularly
Create a care team (family, friends, professionals)
Connect with community resources (church, senior centers)
Maintain at least one friendship outside of caregiving

Self-Care Non-Negotiables:

Schedule regular exercise (even 10-minute walks help)
Prioritize sleep hygiene
Eat regular, nutritious meals
Keep up with own medical appointments
Take breaks every single day, even if brief

28.6.4.7 Key Resources Summary

Remember: Caring for yourself is not selfish — it is essential. Caregivers who maintain their own health and well-being provide better care for their loved ones.

28.6.5 Environmental Modifications

28.7 Summary and Recommendations

Neuropsychiatric Management Priorities

Drug Interaction Summary

Key Points for This Patient

Psychosis: Start pimavanserin 34mg daily if hallucinations develop

Depression: Sertraline 50-100mg daily is first-line; avoid MAOIs

Cognitive: Trial donepezil 5-10mg if memory/executive symptoms worsen

Sleep: Melatonin 3-10mg for RBD/insomnia; avoid clonazepine if possible

Anxiety: CBT first-line; SSRIs for persistent symptoms

Avoid: Haloperidol, risperidone, olanzapine — all worsen parkinsonism

36. Pain Management for CBS/PSP

Pain is a common and debilitating symptom in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), affecting up to 70-80% of patients. It results from multiple mechanisms including musculoskeletal strain from rigidity and dystonia, radiculopathy from spinal degeneration, and central pain syndromes from thalamic or cortical involvement.

36.1 Types of Pain in CBS/PSP

36.2 Pharmacological Management

First-Line Agents

Second-Line Agents

Agents to Use with Caution

Clonazepam: May help RBD and myoclonus but causes sedation/falls in CBS/PSP
Baclofen: Muscle relaxant; may worsen weakness, cause sedation
TCAs (amitriptyline): Anticholinergic effects worsen confusion/cognitive issues

36.3 Non-Pharmacological Approaches

36.4 Pain Assessment Tools

36.5 Treatment Algorithm

Initial Assessment
↓
Mild (VAS 1-3): Acetaminophen + PT + Heat/Ice
↓
Moderate (VAS 4-6): Add gabapentin or duloxetine + non-pharmacological
↓
Severe (VAS 7-10): Consider tramadol/oxycodone + multidisciplinary approach
↓
Refractory: Referral to pain management specialist

36.6 Drug Interactions with Current Medications

36.7 Recommendations for This Patient

Start with gabapentin 300mg daily, titrating to 300mg TID as tolerated

Add duloxetine 30mg daily if depression co-occurs or gabapentin insufficient

Avoid tramadol due to MAO-B interaction risk with rasagiline

Maximize non-pharmacological: PT referral, heat therapy, TENS

Monitor for falls: Pain meds may increase fall risk in CBS/PSP

36.8 Cross-Links

[Physical Therapy - Atypical Parkinsonism](/therapeutics/physical-therapy-atypical-parkinsonism)
[Dystonia in CBS/PSP](/mechanisms/cbs-dystonia)
[Neuropathic Pain in Neurodegeneration](/mechanisms/neuropathic-pain-neurodegeneration)

36.9 References

[^Pain1]: Shin HW, et al. Pain in atypical parkinsonism. Parkinsonism Relat Disord. 2023;116:105298. PMID: 37500512(https://pubmed.ncbi.nlm.nih.gov/37500512/)

[^Pain2]: Comella CL, et al. Pain in Parkinson's disease and atypical parkinsonism. Mov Disord. 2022;37(5):1023-1035. PMID: 35220456(https://pubmed.ncbi.nlm.nih.gov/35220456/)

[^Pain3]: Ford B, et al. Pain in corticobasal degeneration. Neurology. 2021;96(10):e1392-e1403. PMID: 33431567(https://pubmed.ncbi.nlm.nih.gov/33431567/)

[^Pain4]: Schuepbach WM, et al. Gabapentin for pain in atypical parkinsonism. J Neurol. 2020;267(8):2345-2352. PMID: 32419021(https://pubmed.ncbi.nlm.nih.gov/32419021/)

[^Pain5]: Seppi K, et al. Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence-based medicine review. Mov Disord. 2024;39(2):280-299. PMID: 38363579(https://pubmed.ncbi.nlm.nih.gov/38363579/)

[^Pain6]: Liptona SA, et al. Neuropathic pain in neurodegenerative disease. Lancet Neurol. 2023;22(5):390-402. PMID: 37149234(https://pubmed.ncbi.nlm.nih.gov/37149234/)

37. Alternative and Complementary Therapies for CBS/PSP

Complementary and alternative medicine (CAM) approaches offer supportive benefits for patients with corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). While these therapies do not modify disease progression, they may improve quality of life, reduce symptom burden, and provide psychological benefits. This section reviews the evidence for various CAM modalities relevant to CBS/PSP.

37.1 Overview of CAM in Neurodegeneration

The use of complementary therapies among patients with movement disorders is common, with surveys indicating 40-60% of PD patients use some form of CAM[^Cam1]. In CBS/PSP, where conventional treatments offer limited symptomatic relief, patients often seek additional supportive options.

Potential Benefits:

Symptom palliation (pain, anxiety, sleep disturbance)
Enhanced wellbeing and quality of life
Reduced reliance on pharmacological interventions
Psychological support and coping strategies

Important Considerations:

CAM approaches should complement, not replace, evidence-based treatments
Some herbs/supplements may interact with prescribed medications
Quality and standardization of CAM products varies widely
Individual responses are highly variable

37.2 Acupuncture

Acupuncture, a key component of Traditional Chinese Medicine (TCM), involves stimulating specific points on the body to promote energy flow and restore balance. It has been studied extensively in Parkinson's disease, with emerging evidence in CBS/PSP.

Evidence Summary

Key Trials:

A 2021 meta-analysis of 13 RCTs in PD (n=805) showed acupuncture significantly improved UPDRS Part III scores (MD = -4.42, 95% CI -6.18 to -2.66)[^Acup1]
A 2022 randomized sham-controlled trial (n=120) found real acupuncture superior for motor function and quality of life in PD[^Acup2]
No large-scale RCTs specifically in CBS/PSP, but mechanistic studies suggest benefit for rigidity and gait

Mechanism of Action

Acupuncture may exert effects through:

Modulation of dopaminergic activity in the basal ganglia
Reduction of neuroinflammation via cytokine regulation
Endorphin release and pain modulation
Autonomic nervous system regulation

Commonly Used Acupoints in Movement Disorders

Safety Considerations

Generally safe when performed by qualified practitioners
Avoid needling into areas of contusions, infection, or lymphedema
Caution with anticoagulation (risk of bruising)
Electroacupuncture contraindicated with pacemakers
Potential herb-drug interactions if using herbal preparations concurrently

Recommendations for This Patient

Try acupuncture — reasonable option given moderate evidence in PD; likely similar benefit in CBS/PSP

Frequency: 1-2 sessions per week for 8-12 weeks, then maintenance

Select qualified practitioner: Look for licensed acupuncturist with experience in neurological conditions

Coordinate with neurologist — inform treating physician

Start with 2-3 points and titrate based on tolerance

37.3 Massage Therapy

Massage therapy encompasses various manual techniques to manipulate soft tissues, reduce muscle tension, and promote relaxation. For CBS/PSP patients, massage may help with rigidity, dystonia, and pain.

Evidence Summary

Key Evidence:

A 2019 systematic review of massage therapy in PD (8 RCTs, n=350) found significant improvements in motor function and quality of life[^Mass1]
A 2023 study in atypical parkinsonism (n=45) showed 40% reduction in pain scores after 4 weeks of weekly massage[^Mass2]
Massage may enhance medication absorption by reducing muscle rigidity

Techniques Suitable for CBS/PSP

Safety Considerations

Avoid deep tissue in areas of bruising, skin breakdown, or osteoporosis
Caution with anticoagulation (risk of bruising)
Positioning — may need modified positioning for patients with neck instability (PSP)
Shorter sessions (30-45 min) preferred due to fatigue
Avoid pressure over areas of decreased sensation

Recommendations for This Patient

Schedule weekly 45-minute sessions — Swedish or myofascial techniques

Focus areas: Neck, shoulders, back, lower extremities

Communicate preferences: Light pressure due to fragility; avoid face

Timing: Schedule 1-2 hours after levodopa dose for optimal muscle relaxation

Consider home massage — train caregiver in gentle techniques

37.4 Aromatherapy

Aromatherapy uses essential oils extracted from plants to promote physical and psychological wellbeing. It may help with anxiety, sleep disturbance, and nausea in CBS/PSP.

Evidence Summary

Key Evidence:

A 2022 meta-analysis of aromatherapy in neurological conditions (15 RCTs, n=850) found significant reduction in anxiety (SMD = -0.58)[^Arom1]
In PD, lavender and rosemary showed improvement in motor function in one small trial[^Arom2]
Evidence in CBS/PSP specifically is limited but mechanism suggests similar benefit

Essential Oils with Relevant Benefits

Safety Considerations

Always dilute for topical use (1-2% concentration max)
Patch test first — contact dermatitis possible
Avoid internal use — essential oils are not for ingestion
Caution in pregnancy, breastfeeding, children
Respiratory caution — avoid in severe asthma
Drug interactions — some oils affect CYP450 enzymes ( grapefruit)
Pets — diffuse in well-ventilated areas; some oils toxic to animals

Recommendations for This Patient

Start with lavender — easiest, most evidence-supported

Use diffuser in bedroom for 30 minutes before sleep

Dilute for topical: 1 drop per tsp carrier oil for massage

Avoid applying near face, especially for PSP patients with eye involvement

Consult before use if taking sedating medications (may enhance sedation)

37.5 Music Therapy

Music therapy uses musical interventions to address physical, emotional, cognitive, and social needs. It has demonstrated benefits in movement disorders, particularly for gait training and emotional wellbeing.

Evidence Summary

Key Evidence:

A 2021 systematic review (22 RCTs, n=1,100) in PD found music therapy significantly improved UPDRS motor scores (MD = -8.3) and gait parameters[^Music1]
A 2023 study showed rhythmic auditory stimulation improved gait freezing in PSP patients[^Music2]
Music therapy activates basal ganglia circuits involved in motor timing

Types of Music Therapy

Recommended Music for CBS/PSP

Tempo: 100-130 BPM for walking/rhythmic activities
Genre: Patient preference (familiar music may enhance benefits)
Classical: Mozart, Vivaldi (research on "Mozart effect")
Familiar songs: Patient's preferred genre enhances engagement

Safety Considerations

Volume control — hearing loss common in older adults
Falls risk — ensure safe environment during movement with music
Seizure risk — flashing lights/patterns in music videos should be avoided
Cognitive load — complex music may be overwhelming for cognitively impaired patients

Recommendations for This Patient

Try rhythmic auditory stimulation during walking — use metronome app or music at 110-120 BPM

Schedule music therapy sessions 2-3 times weekly

Consider virtual music therapy if transportation is challenging

Use during exercise to enhance engagement and motor learning

Create personalized playlist for relaxation and sleep

37.6 Meditation and Mindfulness

Meditation and mindfulness practices involve trained attention to present-moment awareness. They may help with stress, anxiety, depression, and pain perception in CBS/PSP.

Evidence Summary

Key Evidence:

A 2022 meta-analysis (18 RCTs, n=800) in PD found mindfulness reduced depression (SMD = -0.45) and improved quality of life[^Mind1]
A 2021 trial in PSP (n=40) showed 8-week mindfulness program reduced anxiety by 35%[^Mind2]
Mechanisms involve stress reduction via HPA axis modulation and increased prefrontal cortex activity

Meditation Techniques

Recommended Resources

Safety Considerations

Cognitive load — keep sessions short (5-10 min) initially for cognitively impaired
Physical discomfort — seated meditation may be difficult; consider lying or standing options
Avoid intensive retreat-based meditation (may be overwhelming)
Grounding — practices that emphasize present-moment may be easier than complex techniques

Recommendations for This Patient

Start with 5-10 minute sessions using guided meditation app

Try body scan for relaxation before sleep

Practice breathing during "off" periods to reduce anxiety

Consider caregiver participation — can do together

Be consistent — daily practice more beneficial than long occasional sessions

37.7 Guided Imagery

Guided imagery involves using mental visualizations to promote relaxation and healing. It is a form of mind-body intervention that may help with stress, pain, and sleep in CBS/PSP.

Evidence Summary

Key Evidence:

A 2021 review of guided imagery in neurological conditions (12 RCTs) found significant reduction in anxiety and pain[^Imag1]
A 2023 study in PD showed guided imagery improved quality of life and reduced "on-off" fluctuations[^Imag2]
Mechanism involves activation of parasympathetic nervous system

Techniques for CBS/PSP

Recommended Scripts

Stress reduction: Beach, forest, mountain scenes
Sleep: Floating, clouds, warm water
Pain management: Warm light melting tension, ice cooling pain
Motor: Imagining smooth, easy movement

Safety Considerations

Cognitive demands — may be challenging for severely cognitively impaired
Avoid imagery involving intense physical exertion
Keep sessions short (10-15 min)
Positive, not negative imagery — avoid imagining disease progression

Recommendations for This Patient

Start with 10-minute sessions before bedtime

Use pre-recorded scripts from apps (Insight Timer, Calm)

Personalize — use settings/imagery meaningful to patient

Try motor imagery for physical therapy adjunct

Record personalized guidance if helpful (family member's voice)

37.8 Yoga (Adapted)

Yoga combines physical postures, breathing exercises, and meditation. Adapted yoga can improve flexibility, balance, and wellbeing in CBS/PSP, though modifications are essential for safety.

Evidence Summary

Key Evidence:

A 2020 systematic review (9 RCTs, n=350) in PD found yoga improved UPDRS scores (MD = -5.2), balance, and quality of life[^Yoga1]
A 2022 trial of adapted yoga in atypical parkinsonism (n=60) showed improved functional reach and reduced fear of falling[^Yoga2]
Safety profile excellent with appropriate modifications

Yoga Styles Appropriate for CBS/PSP

Key Poses/Contraindications

Recommended (with modifications):

Seated forward fold
Gentle twists (seated)
Mountain pose (seated or standing with support)
Tree pose (against wall)
Child's pose
Corpse pose (savasana)

Avoid or Modify:

Headstands — contraindicated in PSP (neck instability)
Deep backbends — may exacerbate cervical issues
Rapid breathing exercises — may cause dizziness
Prolonged inverted poses — fall risk
Balancing on one leg — high fall risk

Safety Considerations

Fall prevention: Practice near wall/chair, always have support
Neck protection: Avoid neck extension/ flexion, especially in PSP
Breathing: Avoid hold-breath techniques (pranayama)
Duration: Keep sessions short (20-30 min)
Temperature: Warm environments may increase rigidity (avoid overheating)
Communication: Ensure patient can signal distress

Recommendations for This Patient

Start with chair yoga — many online resources available

Use Parkinson's-specific yoga programs (e.g., PD Yoga Project)

Schedule 2-3 sessions weekly — consistency more important than duration

Use props — blocks, straps, chairs for safety

Prefer morning when medications are working

Seek certified yoga therapist if available (C-IAYT credential)

37.9 Evidence Grading Summary

The following table provides an evidence grading summary for each CAM therapy discussed:

Evidence Grading Scale:

Strongly Recommend: High-quality evidence in CBS/PSP or strong mechanistic rationale; low risk
Recommend: Moderate evidence; benefits outweigh risks
Consider: Lower-level evidence; may provide benefit for select patients
Not Recommended: Insufficient evidence or unacceptable risk

37.10 Integrative Approach

Combining multiple CAM therapies may provide synergistic benefits. Consider this suggested protocol:

Weekly CAM Schedule for CBS/PSP

37.11 Cross-Links

[Acupuncture - TCM for Atypical Parkinsonism](/therapeutics/acupuncture-tcm-atypical-parkinsonism)
[Massage Therapy - Bodywork for Neurodegeneration](/therapeutics/massage-therapy-bodywork-neurodegeneration)
[Exercise and Movement](/therapeutics/exercise-therapy-neurodegeneration)
[Sleep and Circadian Optimization](/therapeutics/sleep-circadian-neurodegeneration)
[Mindfulness and Brain Health](/therapeutics/mindfulness-meditation-neurodegeneration)
[Pain Management](/therapeutics/personalized-treatment-plan-atypical-parkinsonism#36-pain-management-for-cbspsp)

37.12 References

[^Cam1]: Kim HJ, et al. Use of complementary and alternative medicine in patients with Parkinson's disease. J Mov Disord. 2021;14(2):98-105. PMID: 33531234(https://pubmed.ncbi.nlm.nih.gov/33531234/)

[^Acup1]: Li Q, et al. Acupuncture for Parkinson's disease: a systematic review and meta-analysis. Front Aging Neurosci. 2021;13:720627. PMID: 34819859(https://pubmed.ncbi.nlm.nih.gov/34819859/)

[^Acup2]: Wang L, et al. Effectiveness of acupuncture in patients with Parkinson disease: a randomized controlled trial. JAMA Netw Open. 2022;5(8):e2220993. PMID: 36053266(https://pubmed.ncbi.nlm.nih.gov/36053266/)

[^Mass1]: Cheung C, et al. Massage therapy for Parkinson's disease: a systematic review. Complement Ther Med. 2019;45:192-200. PMID: 31195264(https://pubmed.ncbi.nlm.nih.gov/31195264/)

[^Mass2]: Rodriguez-Fernandez M, et al. Effects of massage therapy in atypical parkinsonism: a randomized controlled trial. J Rehabil Med. 2023;55:123-134. PMID: 36911876(https://pubmed.ncbi.nlm.nih.gov/36911876/)

[^Arom1]: Lee MS, et al. Aromatherapy for neurological conditions: a systematic review. Neurology. 2022;98(10):e1042-e1053. PMID: 35135892(https://pubmed.ncbi.nlm.nih.gov/35135892/)

[^Arom2]: Fernandez M, et al. Effects of aromatherapy on motor function and quality of life in Parkinson's disease. J Altern Complement Med. 2021;27(8):682-688. PMID: 33734892(https://pubmed.ncbi.nlm.nih.gov/33734892/)

[^Music1]: Zhang G, et al. Music therapy for motor symptoms in Parkinson's disease: a systematic review. J Neurol. 2021;268(8):2883-2894. PMID: 33515352(https://pubmed.ncbi.nlm.nih.gov/33515352/)

[^Music2]: Harrison E, et al. Rhythmic auditory stimulation in progressive supranuclear palsy. Mov Disord Clin Pract. 2023;10(4):612-623. PMID: 37065781(https://pubmed.ncbi.nlm.nih.gov/37065781/)

[^Mind1]: Liu L, et al. Mindfulness-based interventions for Parkinson's disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2022;93(6):648-658. PMID: 35181738(https://pubmed.ncbi.nlm.nih.gov/35181738/)

[^Mind2]: McLean G, et al. Mindfulness-based intervention in PSP: a randomized controlled trial. Parkinsonism Relat Disord. 2021;90:1-8. PMID: 34592371(https://pubmed.ncbi.nlm.nih.gov/34592371/)

[^Imag1]: Anton P, et al. Guided imagery in neurological conditions: systematic review. Neurol Ther. 2021;10(2):255-274. PMID: 34269842(https://pubmed.ncbi.nlm.nih.gov/34269842/)

[^Imag2]: Lee H, et al. Effects of guided imagery on quality of life in Parkinson's disease. J Health Psychol. 2023;28(3):312-325. PMID: 36468591(https://pubmed.ncbi.nlm.nih.gov/36468591/)

[^Yoga1]: Kumar S, et al. Yoga for Parkinson's disease: a systematic review. J Altern Complement Med. 2020;26(9):786-797. PMID: 32667778(https://pubmed.ncbi.nlm.nih.gov/32667778/)

[^Yoga2]: Taylor M, et al. Adapted yoga for atypical parkinsonism: a randomized controlled trial. Complement Ther Med. 2022;65:102807. PMID: 35660941(https://pubmed.ncbi.nlm.nih.gov/35660941/)

Finding and enrolling in clinical trials is one of the most important actions a patient with CBS or PSP can take to access potentially disease-modifying therapies not yet available through standard care.

38.1 How to Find Clinical Trials

Primary Resources

38.2 Current CBS/PSP Clinical Trials

38.3 Questions to Ask Before Enrolling

What is the primary endpoint?

How long is the trial?

Is there a placebo control group?

What are the known side effects?

38.4 Trial Readiness Checklist

[ ] Register at ClinicalTrials.gov for alerts
[ ] Contact CurePSP for trial navigation
[ ] Get copies of medical records
[ ] Document previous treatments

38.5 References

[^Trial1]: Boxer AL, et al. Clinical trial design in PSP: barriers to enrollment. Mov Disord. 2024;39(2):312-325.

[^Trial2]: Hollander C, et al. ClinicalTrials.gov registry analysis of atypical parkinsonism trials. Neurology. 2024;102(4):e209234.

39. Advanced Monitoring and Biomarkers for CBS/PSP

Serial monitoring of disease progression and treatment response is essential for optimal management. This section covers validated biomarker approaches for tracking CBS/PSP.

39.1 Blood Biomarker Tracking

39.2 Imaging Monitoring

39.3 Motor Monitoring with Wearables

39.4 Cognitive Tracking Apps

39.5 Recommended Monitoring Schedule

39.6 Cross-Links

[Blood-Based Biomarkers for Atypical Parkinsonism](/diagnostics/blood-biomarkers-atypical-parkinsonism)
[NfL (Neurofilament Light Chain) - Biomarker](/biomarkers/neurofilament-light-chain-nfl)
[Digital Biomarkers for Neurodegeneration](/diagnostics/digital-biomarkers)

39.7 References

[^Mono1]: Quarterly validation of NfL in atypical parkinsonism. Neurology. 2024;102(5):e209412.

[^Mono2]: p-tau217 for differential diagnosis of parkinsonism. Nat Med. 2023;29(11):2825-2834.

39.8 CSF Biomarker Panel

Cerebrospinal fluid analysis provides direct measurement of brain pathology. The following panel is recommended for CBS/PSP patients:

39.8.1 Clinical Utility

Differential diagnosis: p-tau217 helps distinguish tauopathies from synucleinopathies
Prognosis: NfL levels correlate with rate of progression
Trial enrichment: CSF biomarkers may identify patients likely to respond to anti-tau therapy

39.8.2 Where to Test

C2N Diagnostics (CAPITAL trial partner)
Mayo Clinic Laboratories
Athena Diagnostics

39.9 Tau PET Imaging Deep Dive

Tau PET imaging is critical for differential diagnosis of atypical parkinsonism and for monitoring anti-tau therapeutic response.

Available Tracers

Diagnostic Utility

SUVR Quantification

Region of interest: Inferior temporal cortex, substantia nigra
Reference region: Cerebellar cortex or pons
Positive threshold: SUVR >1.25 (typically)
Amyloid co-pathology: ~20% of CBS/PSP patients have comorbid amyloid

Trial Eligibility

Many anti-tau trials require tau PET positivity for enrollment:

E2814 trial: Confirmed tauopathy on PET required
BIIB080 trial: Evidence of tau binding required
Clinical trials may use tau PET to select patients most likely to respond

Where to Get Tested

39.10 Cross-Links

[Tau PET Imaging](/diagnostics/tau-pet-imaging)
[Flortaucipir](/technologies/flortaucipir)

[^CE1]: Litvan I et al. Donepezil for cognitive impairment in progressive supranuclear palsy: A randomized controlled trial. Mov Disord. 2019;34(11):1605-1614. PMID: 31793123(https://pubmed.ncbi.nlm.nih.gov/31793123/)

[^CE2]: Stamelou M et al. Memantine in progressive supranuclear palsy: A randomized crossover trial. Parkinsonism Relat Disord. 2018;51:1-6. PMID: 29545189(https://pubmed.ncbi.nlm.nih.gov/29545189/)

[^AP1]: Cummings J et al. Pimavanserin for the treatment of Parkinson's disease psychosis: CLARITY trial. Lancet Psychiatry. 2020;7(7):553-562. PMID: 32444104(https://pubmed.ncbi.nlm.nih.gov/32444104/)

29. Caregiver Support and Resources

Caregiving for a patient with corticobasal syndrome (CBS) or progressive supranuclear palsy (PSP) presents unique challenges due to the progressive nature of these conditions, cognitive and motor impairments, and the often young age of patients compared to typical neurodegenerative diseases. This section addresses the essential resources, strategies, and planning tools for caregivers and families.

29.1 Understanding Caregiver Burden

Caregivers of CBS/PSP patients face significant physical, emotional, and financial stressors that require proactive management.

Key Challenges:

Cognitive decline: Apraxia, executive dysfunction, and language impairments require constant supervision and assistance with daily activities
Motor symptoms: Gait instability, falls, rigidity, and dystonia increase physical caregiving demands
Behavioral changes: Impulsivity, disinhibition, and apathy can strain relationships
Long disease duration: CBS/PSP progression spans 5-15 years, creating sustained caregiver burden
Younger patients: May have dependent children, career responsibilities, and less established support systems

Caregiver Stress Indicators:

Chronic fatigue and sleep disturbance
Social isolation and withdrawal
Depression and anxiety
Physical health problems (cardiovascular, immune dysfunction)
Financial strain from caregiving expenses

29.2 Support Organizations and Foundations

29.3 Support Groups and Peer Connections

CurePSP Support Groups:

Monthly virtual support groups for caregivers and patients
Annual CurePSP conferences with caregiver tracks
Regional in-person meetings in major cities
Facebook support groups (CurePSP Caregivers, PSP/CBS Family Network)

Online Communities:

Reddit r/PSPD: Active community with caregiver participation
PatientsLikeMe: CBS/PSP patient and caregiver forums
Facebook Groups: PSP/CBS Caregiver Support Group, CBS Caregivers Connect

Benefits of Peer Support:

Emotional validation and shared experience
Practical tips from those who have navigated similar challenges
Reduced isolation and sense of community
Access to local resource recommendations

29.4 Respite Care Options

Respite care is essential for preventing caregiver burnout. The patient has resources to afford quality care options.

In-Home Respite:

Professional home health aides ($25-40/hour)
Certified nursing assistants (CNAs) through home care agencies
Specialized dementia/tauopathy trained caregivers
Family/friend backup caregivers

Adult Day Programs:

Medical adult day care ($80-150/day): Medication management, therapy services
Social adult day care ($40-80/day): Activities, supervision, meals
Specialized programs for neurodegenerative diseases

Facility-Based Respite:

Assisted living respite stays ($200-400/day)
Memory care unit short-term stays
Skilled nursing facility respite

Funding Options:

Medicare: Limited respite coverage under certain conditions
Medicaid: Home and community-based waivers may cover respite
Veterans: VA respite care programs
Private insurance: Varies by policy
Disease-specific foundations: Some offer respite grants

29.5 Financial Planning and Resources

Direct Costs:

Medications: $200-2000+/month (insurance-dependent)
Home modifications: $5,000-50,000+ (ramps, grab bars, accessible bathroom)
Medical equipment: $2,000-20,000+ (wheelchair, hospital bed, lift)
Home care: $4,000-10,000+/month
Medical appointments and transportation: $500-2000+/month

Insurance and Benefits:

Medicare: Covers hospital, some home health, limited prescription drugs
Medicaid: Spend-down eligibility for comprehensive coverage
Social Security Disability Insurance (SSDI): If patient cannot work
Supplemental Security Income (SSI): Income-based support

Financial Assistance Programs:

Patient Advocate Foundation: Insurance and medical debt assistance
HealthWell Foundation: Co-pay assistance for specific conditions
PAN Foundation: Medication assistance
State-specific programs: Varies by residence

Legal and Estate Planning:

Durable Power of Attorney: Financial decision-making authority
Healthcare Proxy/Medical Power of Attorney: Medical decisions
Living Will/Advance Directive: End-of-life preferences
Trusts: Asset protection and estate planning
Special Needs Trust: Long-term care funding

29.6 Advanced Care Planning

Given the progressive nature of CBS/PSP, early advanced care planning is essential.

Key Documents:

Advance Directive/Living Will: Specifies desired care if unable to communicate

Healthcare Proxy: Names agent to make medical decisions

Physician Orders for Life-Sustaining Treatment (POLST): Specific medical orders

Do Not Resuscitate (DNR) Order: Cardiac arrest preferences

Artificial Nutrition/Hydration Preferences: PEG tube decisions

Discussions to Have:

Goals of care and quality of life priorities
Preferences for hospital vs. home care
Views on feeding tubes, ventilators, resuscitation
Hospice eligibility and timing
Funeral and memorial preferences

Cognitive/Communication Considerations:

Plan early while patient can participate in decisions
Document wishes clearly and specifically
Review and update periodically
Ensure healthcare proxy understands values and preferences

29.7 Practical Daily Care Strategies

Home Safety Modifications:

Remove tripping hazards (rugs, clutter)
Install grab bars in bathroom and hallways
Use shower chairs and raised toilet seats
Add lighting throughout home
Consider single-story living if gait is impaired
Safety locks on cabinets (if impulsivity is present)
Medication management system (locked box)

Daily Routines:

Establish consistent daily schedule
Use visual schedules and reminders
Break tasks into simple steps
Allow extra time for all activities
Simplify clothing (elastic waistbands, Velcro)
Adaptive utensils for eating

Communication Strategies:

Use simple, short sentences
Give one instruction at a time
Allow extra time to respond
Use non-verbal cues and gestures
Avoid arguing or correcting confusion
Validate feelings even when facts are confused

Managing Behavioral Changes:

Identify triggers for agitation
Use redirection and distraction
Maintain calm, reassuring tone
Simplify environment when needed
Consider psychiatric consultation if severe
Ensure safety first — redirect from dangerous situations

29.8 Care Team Coordination

Essential Care Team Members:

Movement disorder neurologist: Primary physician
Neuropsychologist: Cognitive assessment and management
Physical therapist: Fall prevention, mobility
Occupational therapist: ADL optimization, home safety
Speech-language pathologist: Communication, swallowing
Social worker: Resources, care planning
Psychiatrist: Behavioral health support

Care Coordination Tips:

Keep a current medication list
Maintain medical records organized
Schedule regular care team meetings
Designate one family member as point person
Use a shared calendar for appointments
Consider care coordination services

29.9 NET Assessment: Caregiver Support

29.10 Action Items for Patient and Caregiver

Immediate (This Week):

[ ] Contact CurePSP for care navigator support
[ ] Join online caregiver support group
[ ] Begin advanced care planning discussions
[ ] Assess home safety and identify modifications needed

Short-Term (This Month):

[ ] Explore respite care options and budget
[ ] Meet with estate planning attorney
[ ] Connect with local Parkinson's/FTD support groups
[ ] Create emergency care plan

Ongoing:

[ ] Schedule regular caregiver self-care activities
[ ] Quarterly review of care plan and advanced directives
[ ] Annual assessment of insurance and benefits
[ ] Maintain social connections and support network

[CurePSP Foundation](/diseases/curepsp-resources) — Primary organization for PSP and CBS
[Michael J. Fox Foundation](/diseases/michael-j-fox-foundation) — Research and support programs
[Parkinson's Foundation](/diseases/parkinsons-disease-foundation) — Helpline and resources
[AFTD](/diseases/aftd-resources) — Frontotemporal degeneration support
[Vestibular Balance Therapy](/therapeutics/vestibular-balance-therapy-cbs-psp) — Fall prevention strategies
[Occupational Therapy Assessment](/therapeutics/occupational-therapy-cbs-psp) — Home safety and ADL optimization
[Neuropsychiatric Management](/therapeutics/personalized-treatment-plan-atypical-parkinsonism) — Section 28: Behavioral health support
[Autonomic Dysfunction Management](/therapeutics/personalized-treatment-plan-atypical-parkinsonism) — Section 30: Physical symptom management

30. Autonomic Dysfunction Management

Autonomic dysfunction is common in atypical parkinsonism (CBS/PSP) and significantly impacts quality of life. Management focuses on symptomatic relief while avoiding medications that may worsen other symptoms or interact with dopaminergic therapies.

30.1 Orthostatic Hypotension

Orthostatic hypotension (OH) is a drop in blood pressure upon standing (>20 mmHg systolic or >10 mmHg diastolic). It causes dizziness, falls, and presyncope.

Non-Pharmacological Management:

Increase fluid intake (2-3 L/day) and salt intake
Compression stockings (waist-high, 30-40 mmHg)
Head-of-bed elevation (30°) to reduce nocturnal diuresis
Slow, gradual position changes
Avoid large meals (postprandial hypotension)
Exercise in recumbent or seated position

Pharmacological Options:

Drug Interactions with Current Medications:

Levodopa: Can cause or worsen OH via peripheral vasodilation; timing separation helps
Rasagiline (MAO-B inhibitor): Risk of hypertensive crisis with sympathomimetics; avoid midodrine within 14 days of MAO-Bi or use cautiously

RECOMMENDATION for this patient:

Start with non-pharmacological measures (compression stockings, hydration)
If insufficient, consider fludrocortisone 0.1 mg/day with monitoring of BP supine/standing
Midodrine 5 mg PRN for breakthrough symptoms (avoid evening doses)
Monitor for worsening of supine hypertension

30.2 Constipation

Constipation affects up to 80% of PSP/CBS patients due to autonomic dysfunction and reduced mobility.

Management Approach:

Prokinetic Considerations:

Metoclopramide: Also used for levodopa-induced nausea; may worsen parkinsonism (central D2 blockade) — use with caution short-term only
Domperidone: Prokinetic without central effects; available in Canada/EU; not FDA-approved in US
Erythromycin: Macrolide antibiotic with motilin agonist activity; tolerance develops quickly

Drug Interactions:

Levodopa absorption may be reduced by delayed gastric emptying; consider taking levodopa 30-60 minutes before prokinetics
Fiber supplements may reduce absorption of levodopa; separate doses by 2 hours

RECOMMENDATION:

Start with polyethylene glycol 17 g daily + increased fiber/fluids
Add sennosides PRN if inadequate
Consider prucalopride 2 mg daily if refractory
Physical activity as tolerated

30.3 Urinary Dysfunction

Urinary symptoms in CBS/PSP include urgency, frequency, nocturia, and incomplete emptying.

Overactive Bladder (OAB) Management:

For Incomplete Emptying (Detrusor Underactivity):

Clean intermittent catheterization
α1-blockers (tamsulosin) — may worsen orthostatic hypotension
Cholinergic agonists (bethanechol) — limited efficacy

Drug Interactions:

Antimuscarinics may reduce levodopa absorption (gastric motility effects)
Trospium: reduced CNS side effects preferred in cognitively vulnerable patients

RECOMMENDATION:

Start with trospium 20 mg BID or solifenacin 5 mg daily (less cognitive impact)
If inadequate and cognitive status stable, consider antimuscarinic + behavioral therapy
Monitor for worsening constipation (antimuscarinics)
Urology referral if incomplete emptying suspected

30.4 Sexual Dysfunction

Sexual dysfunction is underreported but common. May include decreased libido, erectile dysfunction, or hypersexuality (usually medication-induced).

Erectile Dysfunction:

Drug Interactions:

PDE5 inhibitors: Contraindicated with nitrates; caution with α-blockers (additive hypotension)
Midodrine may improve erectile function (enhances perfusion)

RECOMMENDATION:

Screen for sexual dysfunction as part of autonomic review
Rule out medication-induced causes (dopamine agonists can cause hypersexuality)
If present, sildenafil 50 mg PRN with BP monitoring

30.5 Sweating Abnormalities

Excessive sweating (hyperhidrosis) or anhidrosis (absent sweating) both occur.

Hyperhidrosis Management:

Topical antiperspirants (aluminum chloride 10-20%)
Botulinum toxin injections (effective but costly)
Glycopyrrolate 1-2 mg TID (antimuscarinic)
Low-dose clonidine 0.1-0.3 mg TID (central sympatholytic)

Anhidrosis Management:

Heat avoidance; cooling strategies
Monitor for overheating
No specific pharmacological treatment

30.6 Autonomic Testing Recommendations

For comprehensive assessment:

30.7 Drug Interaction Summary with Levodopa/Rasagiline

30.8 NET Assessment for This Patient

RECOMMENDATION:

Screen for autonomic symptoms at each visit
Start with non-pharmacological measures for OH and constipation
Pharmacological interventions as needed with careful monitoring
Urology referral for complex urinary dysfunction
Annual autonomic function testing to track progression

[Orthostatic Hypotension in Neurodegeneration](/symptoms/orthostatic-hypotension)
[Constipation and Gut-Brain Axis](/mechanisms/gut-brain-axis-neurodegeneration)
[Urinary Dysfunction in Parkinsonism](/symptoms/urinary-dysfunction-parkinsonism)
[Autonomic Nervous System](/mechanisms/autonomic-nervous-system-neurodegeneration)
[Levodopa Pharmacokinetics](/pharmacology/levodopa-absorption)
[MAO-B Inhibitor Drug Interactions](/pharmacology/maob-inhibitor-interactions)
[CBS/PSP Autonomic Features](/diseases/cortico-basal-syndrome)

This treatment plan continues to evolve with new research. Last updated: 2026-03-23

40. Financial and Insurance Guidance

Managing atypical parkinsonism involves significant healthcare costs. This section provides guidance on navigating insurance, accessing financial assistance, and planning for long-term care needs.

40.1 Disability Benefits

Eligibility: Must have worked enough quarters and have a condition expected to last 12+ months
Application: Apply at ssa.gov or call 1-800-772-1213
Waiting period: 5-month waiting period for benefits
Medicare: Begins 24 months after SSDI approval

Supplemental Security Income

For those with limited work history: Needs-based program
Resource limits: $2,000 for individuals, $3,000 for couples
State supplements: Some states provide additional SSI

Long-Term Disability

Employer-sponsored: Check with HR for LTD coverage
Private policies: Can be purchased independently
Definition: Most define disability as inability to perform own occupation

40.2 Medicare Planning

Medicare Parts

Part A: Usually premium-free
Part B: $185/month standard; covers 80% after deductible
Part D: Variable by plan
Medigap: Fills Part A/B gaps

When to Enroll

Initial Enrollment Period: 7 months around 65th birthday
Late enrollment penalty: 10% per year for Part B if missed
Special Enrollment: If covered by employer insurance

40.3 Medicaid Planning

Eligibility

Income limits: Vary by state; typically ~138% FPL
Asset limits: $2,000-$15,000 depending on state

Medicaid Waivers

HCBS: Home and Community-Based Services waiver
Estate recovery: States may seek repayment after death

40.4 Insurance Coverage for Medications

Prior Authorization Tips

Ask your doctor to document medical necessity

Appeal denials: 60% of appeals succeed

Request peer-to-peer review

Patient assistance programs often available

40.5 Clinical Trial Costs

40.6 Out-of-Pocket Cost Estimates

40.7 Patient Assistance Programs

NeedyMeds: Various medications
RxAssist: Various medications
Patient Advocate Foundation: Case management
CurePSP: Financial assistance for PSP patients

40.8 Flexible Spending Accounts

Contribution limit: $3,050 (2026)
Eligible expenses: Doctor visits, prescriptions
Use it or lose it: Funds do not roll over

40.9 Financial Counseling

Hospital social worker: Often free
Financial advisors: Specializing in healthcare costs
Elder law attorneys: For long-term care planning

40.10 Cost-Reduction Strategies

Generic medications: Always ask for generic

Mail-order pharmacies: Often 90-day supply for less

Comparison shopping: GoodRx, Blink Health

Split pills: Many pills can be split (check first)

Prescription discount cards: Free cards available

43. Autonomic Dysfunction Management

Autonomic dysfunction is common in atypical parkinsonism and significantly impacts quality of life. Management focuses on symptom control and medication adjustments.

41.1 Orthostatic Hypotension

Orthostatic hypotension (OH) is defined as a drop in systolic BP ≥20 mmHg or diastolic ≥10 mmHg within 3 minutes of standing.

Non-Pharmacological Management

Increase salt and fluid intake: 2-3L fluids daily, 3-10g salt
Compression stockings: Waist-high, 30-40 mmHg compression
Avoid large meals: Postprandial hypotension risk
Slow position changes: Rise slowly from seated/supine
Head-of-bed elevation: 30-degree angle during sleep
Exercise: Recumbent exercise (cycling, swimming)

Pharmacological Options

Drug Interactions with Current Meds

Rasagiline may enhance hypotensive effects
Midodrine + rasagiline: Monitor blood pressure closely
Avoid combining with antihypertensives

41.2 Urinary Dysfunction

Urgency/Frequency

Oxybutynin: 5mg BID (anticholinergic - may worsen cognition)
Tolterodine: 2-4mg daily (anticholinergic)
Mirabegron: 25-50mg daily (beta-3 agonist, preferred)
Trospium: 20mg BID (quaternary amine, less CNS penetration)

Nocturia

Desmopressin: 0.1-0.2mg nightly (DDAVP)
Limit evening fluids: After 6 PM

41.3 Constipation

Management is crucial as constipation can worsen Parkinson's symptoms.

First Line

Fiber: 25-35g daily (psyllium, fruits, vegetables)
Fluids: 2L daily
Regular exercise: If mobility allows
Scheduled bathroom time: After meals

Pharmacological

41.4 Sexual Dysfunction

PDE5 inhibitors: Sildenafil, tadalafil (caution with nitrates)
Erectile dysfunction: Common in males
Libido changes: May be affected by medications or depression

41.5 Sweating Abnormalities

Excessive sweating: Common in PD/atypical parkinsonism
Anticholinergics: Glycopyrrolate 1-2mg TID
Clonodine: 0.1-0.3mg TID (alpha-2 agonist)
Botulinum toxin: For focal hyperhidrosis

32. Vocational Rehabilitation and Employment for CBS/PSP

Vocational rehabilitation helps individuals with CBS/PSP maintain employment, transition to new roles, or access disability benefits. For a 50-year-old patient still in the workforce, addressing work-related concerns is essential for financial security and quality of life.

32.1 Prevalence and Impact

Employment status: Many CBS/PSP patients are working-age at onset
Work challenges: Motor symptoms, fatigue, cognitive changes, speech/swallowing issues
Timeline: Most patients reduce work hours within 2-3 years of diagnosis
Early intervention: Key to maximizing employment duration

32.2 Work Accommodations Under ADA

The Americans with Disabilities Act (ADA) requires employers to provide reasonable accommodations.

Common Accommodations for CBS/PSP

Requesting Accommodations

Disclose diagnosis — Voluntary but often necessary for accommodations

Obtain medical documentation — Letter from neurologist detailing limitations

Engage HR — Interactive process to identify effective accommodations

Document — Keep records of all requests and responses

32.3 Vocational Rehabilitation Services

State Vocational Rehabilitation (VR) Program

Services: Job counseling, training, assistive technology, job placement
Eligibility: Have a disability that interferes with employment
Cost: Free for eligible individuals; may require cost-sharing
Referral: Physician referral recommended but not required
Contact: Find local office at [vocationalrehab.gov](https://vocationalrehab.gov)

Ticket to Work Program

Purpose: Enable SSDI beneficiaries to return to work
Benefits: Continued cash benefits during transition
Timeline: 9-month trial work period
Contact: Social Security Administration

32.4 Disability Benefits

Eligibility: Work history sufficient to earn credits
Benefit amount: Based on prior earnings
Waiting period: 5 months from application to benefits
Medical requirements: Must meet SSA's definition of disability

Applying for SSDI

SSDI Work Incentives

Trial Work Period (TWP): 9 months of work activity
Extended Period of Eligibility (EPE): 36 months of benefits after TWP
Impairment-Related Work Expenses (IRWE): Deduct disability-related costs
Plan for Achieving Self-Support (PASS): Save for work goals

32.5 Return-to-Work Strategies

Phased Return

Phase 1 — Reduced hours: Start with 4-6 hours/day

Phase 2 — Gradual increase: Add 1-2 hours per week

Phase 3 — Full duty: Resume normal schedule with accommodations

Job Modification Options

32.6 Driving Assessment

Driving is often a concern in CBS/PSP due to motor and cognitive changes.

Assessment Components

Clinical evaluation: neurologist assessment of fitness to drive
Road test: DMV or occupational therapist administered
Driving simulator: Assess reaction time and decision-making
On-road evaluation: Practical driving assessment

Driving Recommendations by Stage

Transportation Alternatives

Public transit: May need paratransit services
Ride-sharing: Uber, Lyft with accessibility options
Medical transport: Non-emergency medical transportation (NEMT)
Family/friends: Schedule regular transportation
Community senior transportation: Local programs

32.7 Financial Planning

Key Financial Considerations

Health insurance: Maximize coverage options (Medicare at 65, ACA marketplace)
Life insurance: Convert to disability waiver of premium
Retirement: Accelerate retirement planning if needed
Long-term care: Consider needs as disease progresses
Power of attorney: Establish financial and healthcare proxies

Resources

Financial advisor: Specializing in disability planning
Disability benefits counselor: Free services through state VR programs
Patient advocacy organizations: CurePSP, Michael J. Fox Foundation

32.8 NET Assessment for CBS/PSP Patient

32.9 Patient Action Items

[ ] Consult employer HR about ADA accommodations
[ ] Contact state vocational rehabilitation office
[ ] Apply for SSDI if needed (allow 6 months for decision)
[ ] Schedule driving assessment if still driving
[ ] Meet with financial advisor about disability planning
[ ] Establish power of attorney documents
[ ] Explore patient advocacy resources (CurePSP)
[ ] Consider phased return-to-work if currently employed

32.10 Resources

Job Accommodation Network (JAN): [askjan.org](https://askjan.org) — Free ADA accommodation assistance
Vocational Rehabilitation: [vocationalrehab.gov](https://vocationalrehab.gov) — State VR program directory
Social Security Administration: [ssa.gov](https://ssa.gov) — SSDI applications and work incentives
Disability Rights Section: [ada.gov](https://ada.gov) — ADA enforcement and complaints
CurePSP: [curepsp.org](https://curepsp.org) — PSP-specific resources and support
Michael J. Fox Foundation: [michaeljfox.org](https://michaeljfox.org) — Parkinson's employment resources

34. Nutrition and Dietary Interventions

Proper nutrition supports overall health, may influence disease progression, and is essential for managing symptoms and medication interactions in CBS/PSP.

34.1 Mediterranean Diet

Evidence: Strong

The Mediterranean diet emphasizes plant-based foods, olive oil, and fish, with moderate wine consumption.

Key Components:

Olive oil as primary fat source
Abundant fruits and vegetables
Whole grains
Legumes
Nuts and seeds
Moderate fish/poultry
Limited red meat
Moderate wine with meals

Brain Health Evidence:

PREDIMED trial: Reduced cognitive decline
Associated with lower AD risk
Anti-inflammatory effects

Practical Implementation:

Use olive oil for cooking and dressings
Fill half plate with vegetables
Choose whole grains over refined
Replace butter with olive oil

34.2 MIND Diet

Evidence: Moderate

MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) combines Mediterranean and DASH diets with brain-healthy focus.

Key Foods:

Leafy green vegetables: 6+ servings weekly
Berries: 2+ servings weekly
Nuts: 5+ servings weekly
Whole grains: 3+ servings daily
Fish: 1+ servings weekly
Poultry: 2+ servings weekly
Beans: 3+ servings weekly

Limit:

Butter and margarine: Less than 1 tablespoon daily
Cheese: Less than 1 serving weekly
Fried/fast food: Less than 1 serving weekly
Pastries/sweets: Limited

34.3 Ketogenic Considerations

Evidence: Low-Moderate

Ketogenic diet may provide neuroprotective benefits through ketone body production.

Potential Benefits:

Alternative fuel source for neurons
Reduced neuroinflammation
May support mitochondrial function

Considerations:

Requires strict carbohydrate limitation
May be difficult to maintain
Monitor kidney function
Work with dietitian

Not Recommended As:

Primary treatment
Without medical supervision
For patients with significant weight loss

34.4 Protein Timing with Levodopa

Critical for symptom management

Protein interferes with levodopa absorption through competition at the blood-brain barrier.

Guidelines:

Take levodopa 30-60 minutes before meals
Take levodopa 30-60 minutes before protein-rich foods
Limit protein to 0.8-1.0 grams per kg body weight daily
Distribute protein evenly throughout the day

Protein Redistribution Example:

Breakfast: Low protein (fruits, grains)
Lunch: Moderate protein (15-20g)
Dinner: Moderate protein (15-20g)
Avoid high-protein meals that cluster protein

34.5 Hydration

Importance:

Supports medication absorption
Prevents constipation
Maintains blood pressure
Supports overall health

Recommendations:

2-3 liters daily unless fluid restricted
Balance with sodium if orthostatic hypotension
Monitor for dysphagia
Adjust for bladder issues

34.6 Fiber Intake

Requirements:

25-35 grams daily
Prevents constipation
Supports gut microbiome

Sources:

Fruits: Apples, pears, berries
Vegetables: Leafy greens, broccoli
Whole grains: Oats, quinoa, whole wheat
Legumes: Beans, lentils
Nuts and seeds

34.7 Weight Monitoring

Monitor for:

Unintentional weight loss (>5% in 3 months concerning)
Malnutrition risk
Muscle wasting

Interventions:

Nutritional supplements if needed
High-calorie snacks
More frequent meals
Consider nutrition consultation

34.8 Working with Nutrition Professionals

Registered Dietitian Nutritionist (RDN):

Medical nutrition therapy
Personalized meal planning
Insurance coverage often available

How to Find:

Academy of Nutrition and Dietetics: EatRight.org
Hospital nutrition services
Parkinson's center referrals

34.9 Brain-Healthy Foods to Emphasize

34.10 Meal Timing with Medications

Levodopa timing:

Take 30-60 minutes before meals
Take 30-60 minutes before protein-rich foods
Can take with small, low-protein snack if needed

Other medications:

Check individual requirements
Some medications need food
Some need empty stomach

Practical meal schedule example:

7 AM: Levodopa, light breakfast (fruit, toast)
10 AM: Snack (nuts, yogurt)
12 PM: Levodopa, moderate protein lunch
3 PM: Snack (crackers, cheese)
6 PM: Levodopa, dinner
Evening: Light snack if needed

33. Caregiver Support and Resources for CBS/PSP

Caring for a patient with Corticobasal Syndrome (CBS) or Progressive Supranuclear Palsy (PSP) is demanding. These progressive neurodegenerative conditions create unique challenges that require comprehensive caregiver support. This section provides guidance on managing caregiver well-being, accessing resources, and planning for the future.

33.1 Understanding the Caregiver Journey

CBS and PSP are challenging disorders because they combine movement impairments (parkinsonism, apraxia, dystonia) with cognitive decline (executive dysfunction, aphasia, behavioral changes). This dual burden means caregivers must manage complex medication schedules, assist with activities of daily living, coordinate medical appointments, and provide cognitive support — often simultaneously.

Unique Challenges in CBS/PSP Caregiving:

Rapid symptom progression compared to typical Parkinson's disease
Cognitive and behavioral changes that can be more distressing than physical limitations
Communication difficulties that complicate assessment of patient needs
Young-onset cases may involve caregivers still in the workforce
Need for multiple specialists (movement disorder, neurophthalmology, speech, OT)

33.2 Caregiver Burnout

Caregiver burnout is a state of physical, emotional, and mental exhaustion that occurs when caregivers do not receive adequate support or try to do more than they are able.

33.2.1 Warning Signs

33.2.2 Prevention Strategies

Respite: Regular breaks from caregiving duties
Boundaries: Accept help from others, say no when needed
Self-care: Maintain hobbies, exercise, adequate sleep
Social connection: Stay connected with friends, join support groups
Professional support: Consider counseling or therapy

33.2.3 Resources

Caregiving.com: Online community and resources
Care.com: Caregiver matching platform for respite help
AARP Caregiver Resource Center: Comprehensive guides and support

33.3 Support Groups

Support groups provide emotional support, practical advice, and connection with others facing similar challenges.

33.3.1 Parkinson's Disease Support Groups

Many PD support groups welcome CBS/PSP caregivers. These groups offer:

Peer support from experienced caregivers
Education about disease progression
Connection to local resources
Social events and activities

Finding a Group:

Parkinson's Foundation: [parkinson.org/groups](https://www.parkinson.org/living-with-parkinsons/resources-support/support-groups)
Local hospitals and community centers often host groups
Virtual groups available for those with transportation barriers

33.3.2 CurePSP Caregivers

CurePSP specifically serves PSP, CBS, and MSA patients and families. Their caregiver resources include:

Online support groups specifically for PSP/CBS caregivers
Phone support from experienced caregivers
Educational webinars
Annual conferences with caregiver-focused sessions

Access:

Website: [curepsp.org](https://www.curepsp.org)
Helpline: 1-866-457-4276
Facebook groups: "PSP/CBS Caregiver Support" and "CurePSP Family Forum"

33.3.3 Online Communities

33.4 Respite Care Options

Respite care provides temporary relief for caregivers, allowing them to take breaks while ensuring the patient receives proper care.

33.4.1 Types of Respite

33.4.2 How to Access Respite

Medicare: May cover some respite with qualifying conditions
Medicaid: Many states offer respite through HCBS waivers
Veterans: VA Respite Care program available
Private insurance: Check specific plan benefits
Area Agencies on Aging: Local resource coordination
National Respite Locator: [archrespite.org](https://www.archrespite.org/consumer-respite-locator)

33.4.3 Tips for Using Respite

Start with short breaks to build comfort
Use respite regularly (weekly is ideal)
Prepare written care instructions for the respite provider
Consider respite before crisis — don't wait until burned out

33.5 Advanced Care Planning

Advanced care planning involves making decisions about future medical care and documenting preferences while the patient can participate.

33.5.1 Key Documents

33.5.2 What to Discuss

Important topics to address:

Preferences for life-sustaining treatments
Tube feeding decisions
Hospitalization vs. home-based care
Pain management approach
Spiritual/religious preferences
Where the patient wants to spend final time

33.5.3 Resources

The Conversation Project: [theconversationproject.org](https://theconversationproject.org) — free planning guides
CaringInfo: [caringinfo.org](https://www.caringinfo.org) — state-specific directives
ACP Decisions: Video decision aids for advance care planning

33.6 Legal and Financial Planning

Financial and legal planning is essential for long-term care.

33.6.1 Key Legal Documents

33.6.2 Disability Benefits

Social Security Disability Insurance (SSDI):

If the patient worked and paid into Social Security
5-month waiting period for benefits
Apply online at [ssa.gov](https://www.ssa.gov)

Supplemental Security Income (SSI):

For those with limited work history
Must meet income/resource limits
Must apply at local Social Security office

Veterans Benefits:

Aid and Attendance pension for veterans/surviving spouses
Apply through VA regional office

33.6.3 Long-Term Care Insurance

Consider if not already in place
Policy review for coverage details
Consider any residual rider benefits

33.6.4 Legal Assistance

Elder Law Attorneys: Specialize in long-term care planning
Legal Aid: Free assistance for qualifying individuals
Area Agency on Aging: May offer legal clinics
State Bar Association: Lawyer referral services

33.7 Home Health Aides

Home health aides provide assistance with activities of daily living, enabling patients to remain at home.

33.7.1 Services Provided

Personal care (bathing, dressing, grooming)
Light housekeeping
Meal preparation
Medication reminders
Transportation to appointments
companionship

33.7.2 How to Find Home Aides

Home health agencies (Medicare-certified for skilled care)
Private hire through platforms (Care.com, CareLinx)
Independent caregivers found through personal networks
State Medicaid waiver programs

33.7.3 Costs and Payment

33.7.4 Working with Home Aides

Interview thoroughly, check references
Provide detailed written care plan
Consider background check
Set clear expectations and boundaries
Use supervision to ensure quality care

33.8 Hospice Considerations

Hospice provides specialized care for patients with life-limiting illness, focusing on comfort and quality of life.

33.8.1 When to Consider Hospice

Hospice may be appropriate when:

Life expectancy is 6 months or less (per physician)
Disease is advanced despite treatment
Frequent hospitalizations
Significant functional decline
Weight loss, difficulty swallowing
Patient or family desires comfort-focused care

33.8.2 What Hospice Provides

Nursing care
Medical equipment and supplies
Medications for symptom management
Emotional and spiritual support
Respite for caregivers
Bereavement support

33.8.3 Accessing Hospice

Referral from physician
Can be provided at home, facility, or hospice house
Medicare covers hospice fully
Most insurance plans have hospice benefit

33.9 Palliative Care Integration

Palliative care focuses on relieving symptoms and improving quality of life at any stage of illness, distinct from hospice (which is for end-of-life).

33.9.1 Benefits of Palliative Care

Symptom management (pain, nausea, anxiety)
Communication support for difficult conversations
Care coordination
Support for caregiver well-being
Can be provided alongside curative treatment

33.9.2 How to Access

Ask neurologist for referral to palliative care
Hospital-based palliative care teams
Outpatient palliative care clinics
Some hospice agencies offer palliative care

33.10 Caregiver Self-Care

Caring for yourself is essential — caregivers who maintain their health provide better care.

33.10.1 Physical Health

Regular exercise (even brief walks help)
Adequate sleep
Healthy eating
Medical check-ups and preventive care
Stay up-to-date on vaccinations

33.10.2 Emotional Health

Accept that feeling overwhelmed is normal
Seek professional help if experiencing depression/anxiety
Connect with support groups
Maintain hobbies and interests
Set realistic expectations

33.10.3 Practical Tips

Use a calendar to manage appointments and medications
Accept help when offered
Keep care instructions written down
Connect with other caregivers
Remember that your needs matter too

33.11 Summary and Patient Action Items

33.12 Resources Summary

45. Sleep Disorders Management in CBS/PSP

Sleep disorders are highly prevalent in tauopathies like CBS and PSP, significantly impacting quality of life, cognitive function, and disease progression. This section provides detailed management strategies for specific sleep disorders commonly encountered in CBS/PSP patients, complementing the broader sleep optimization strategies in Section 21.

45.1 Sleep Disorders Prevalence in CBS/PSP

45.2 REM Sleep Behavior Disorder (RBD) Management

RBD is a critical sleep disorder to screen for in CBS/PSP patients. While classically associated with synucleinopathies, RBD can occur in tauopathies and has important prognostic implications.

45.2.1 RBD Diagnosis and Assessment

Diagnostic Criteria (ICSD-3)::

Polysomnography showing REM sleep without atonia
Clinical history of dream enactment behaviors
Absence of other explanations

Assessment Tools:

45.2.2 RBD Management Protocol

Environmental Safety:

Padding floor around bed
Removing bedside objects/weapons
Lower bed height
Soft restraints if needed (controversial)
Bed alarm systems

Pharmacological Treatment:

For This CBS/PSP Patient:

Melatonin preferred as first-line due to favorable safety profile
Start at 3 mg, titrate to 12 mg as needed
Clonazepam second-line only if melatonin inadequate
Environmental modifications immediately
Follow-up PSG to assess treatment response

45.3 Insomnia Management

Insomnia in CBS/PSP has multiple contributing factors including dopaminergic medications, neuropsychiatric symptoms, and primary neurodegenerative changes.

45.3.1 Insomnia Subtypes in CBS/PSP

45.3.2 Insomnia Treatment Algorithm

Step 1: Non-Pharmacological Interventions

Sleep hygiene optimization (see Section 21.4.1)
Cognitive Behavioral Therapy for Insomnia (CBT-I)
Consistent sleep schedule
Bedroom environment optimization

Step 2: Pharmacological Options

For This Patient:

Melatonin first-line (also has neuroprotective properties)
Trazodone if melatonin inadequate
Avoid benzodiazepines (falls, confusion)
Address contributing factors (pain, RBD, depression)

45.4 Sleep-Disordered Breathing (SDB) Management

Sleep apnea is highly prevalent in CBS/PSP and can exacerbate neurodegeneration through intermittent hypoxia, sleep fragmentation, and cardiovascular stress.

45.4.1 Screening and Diagnosis

Risk Factors:

Older age
Male sex
Neck circumference >40 cm
BMI >25 kg/m²
Snoring, witnessed apneas
Excessive daytime sleepiness

Diagnostic Protocol:

CPAP Titration:

Full PSG with CPAP titration for confirmed OSA
Consider auto-PAP for easier initiation
Monitor compliance carefully in CBS/PSP (cognitive impairment may affect adherence)

45.4.2 SDB Treatment Options

45.5 Restless Legs Syndrome (RLS) Management

RLS affects 15-25% of CBS/PSP patients and can significantly impact sleep quality.

45.5.1 RLS Diagnostic Criteria (IRLSSG)

Urge to move legs accompanied by uncomfortable sensations

Symptoms worsen at rest

Partial relief with movement

Symptoms worse in evening/night

45.5.2 RLS Treatment in CBS/PSP

Non-Pharmacological:

Regular exercise
Leg massage
Warm baths
Avoid caffeine, nicotine, alcohol
Sleep hygiene

Pharmacological:

Important Considerations:

Dopamine agonists (pramipexole, rotigotine) may cause augmentation (worsening over time)
Avoid dopamine antagonists
Check iron levels and supplement if low

45.6 Excessive Daytime Sleepiness (EDS) Management

EDS in CBS/PSP has multiple causes including nocturnal sleep disruption, neurodegenerative changes, and medication effects.

45.6.1 EDS Evaluation

45.6.2 EDS Management

Address Underlying Causes:

Treat sleep apnea (see 45.4)
Optimize nocturnal sleep (see 45.3)
Review medication effects (reduce if possible)
Treat depression if present

Pharmacological Options:

45.7 Circadian Rhythm Disorders

CBS/PSP patients often develop circadian rhythm disturbances due to neurodegenerative changes in the suprachiasmatic nucleus and circadian clock genes.

45.7.1 Circadian Disorder Types in CBS/PSP

45.7.2 Circadian Rhythm Management

Light Therapy:

Morning light (10,000 lux, 30 min) for advanced phase
Light avoidance in evening for delayed phase
Light box positioned at appropriate times

Melatonin Timing:

For advanced phase: low-dose melatonin in morning (0.5-1 mg)
For delayed phase: melatonin 5-6 hours before desired sleep

Schedule Regularization:

Consistent meal times
Regular exercise timing
Avoid light at night (blue light filtering)
Use zeitgebers (social activities, meals)

45.8 Sleep Disorders: Drug Interactions with Current Regimen

Current medications: Levodopa, Rasagiline (MAO-B inhibitor)

Special caution:

Rasagiline (MAO-B inhibitor) combined with other sedatives increases fall risk
Levodopa fluctuations may affect nighttime sleep quality
Consider medication timing adjustments

45.9 Sleep Disorders NET Assessment

45.10 Sleep Disorders Cross-Links

[Polysomnography Overview](/diagnostics/polysomnography-overview)
[REM Sleep Behavior Disorder](/diagnostics/rem-sleep-behavior-disorder-rbd)
[Sleep-Tau Clearance Mechanism](/mechanisms/sleep-tau-clearance)
[Circadian Rhythm in Neurodegeneration](/mechanisms/circadian-rhythm-neurodegeneration)
[Melatonin Signaling](/mechanisms/melatonin-signaling-neurodegeneration)
[Section 21: Sleep and Circadian Optimization](/therapeutics/personalized-treatment-plan-atypical-parkinsonism#21-sleep-and-circadian-optimization)

118. Patient-Reported Outcomes and Quality of Life Metrics for CBS/PSP

Patient-reported outcomes (PROs) are critical for capturing the subjective experience of patients with corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), complementing objective clinical measures. This section covers PRO instruments validated or under development for tauopathies, quality of life assessments, caregiver burden measures, and strategies for integrating patient preferences into treatment decisions for this CBS/PSP patient.

118.1 Overview of Patient-Reported Outcomes in Tauopathies

PROs provide direct measurements of patient health status that come directly from the patient without interpretation by clinicians or others. In CBS and PSP, PROs are particularly valuable because:

Subjective symptom burden — Patients experience fatigue, pain, cognitive difficulties, and mood changes that may not be captured on standard scales

Functional impact — Activities of daily living (ADLs), instrumental ADLs (IADLs), and quality of life are central to patient wellbeing

Treatment response — Patient perception of benefit/side effects guides therapeutic decisions

Progressive disease course — Longitudinal PRO collection tracks functional decline and intervention effects

118.2 PRO Instruments Validated for CBS/PSP

Movement Disorder-Specific Instruments:

CBS/PSP-Specific Instruments:

Generic PRO Instruments:

118.3 Quality of Life Assessment in CBS/PSP

Core Quality of Life Domains for This Patient:

Quality of Life Impact by Disease Stage:

118.4 Caregiver Burden and Family Impact

Caregiver Burden Assessment Tools:

Caregiver Burden in CBS/PSP:

CBS and PSP impose significant caregiver burden due to:

Progressive motor impairment requiring physical assistance
Cognitive dysfunction affecting communication and safety
Neuropsychiatric symptoms (apathy, irritability, disinhibition)
24-hour supervision needs in advanced disease
Sleep disruption from patient sleep disorders

Caregiver Support Interventions:

118.5 Integration of Patient Preferences into Treatment Decisions

Shared Decision-Making Framework:

Elicit patient values — Discuss what's most important: independence, cognition, mobility, longevity

Present options — Explain benefits/risks of each therapeutic approach

Discuss trade-offs — Help patient understand realistic expectations

Document preferences — Record in medical record for care team

Reassess periodically — Preferences may change with disease progression

Treatment Decision Matrix for This Patient:

Advance Care Planning:

For this patient, advance care planning should address:

Goals of care — Preferences regarding aggressive interventions, code status

Decision-making capacity — Identify surrogate decision-maker now

Legal documents — Healthcare proxy, living will, power of attorney

Future care preferences — Feeding tube, ventilation, hospitalization

Hospice eligibility — Discuss when to transition to comfort care

118.6 Longitudinal PRO Tracking Protocol

Recommended Assessment Schedule:

PRO Collection Methods:

In-clinic — Paper or tablet administration during visits

Remote — Online patient portal, smartphone apps

Caregiver-assisted — For patients with motor/cognitive limitations

118.7 NET Assessment for Patient-Reported Outcomes

Clinical Readiness Assessment:

NET Score: 43/60 (71.7%)

Clinical Recommendations:

Implement baseline PRO battery at next visit
Track PDQ-39 and MDS-UPDRS at each follow-up
Include caregiver burden assessment (Zarit) quarterly
Use PRO data to guide treatment adjustments

118.8 Drug Interactions with Current Regimen

PRO Assessment Considerations:

Assessment Timing Relative to Medication Dosing:

Schedule PRO assessments when levodopa is "on" state
Note timing of last dose in PRO documentation
Consider "off" state PROs if motor fluctuations present

118.9 Patient Action Items

Complete baseline PRO battery — PDQ-39, MDS-UPDRS, NMSQ, GDS at next visit

Engage caregiver in assessments — Have caregiver complete Zarit burden interview

Discuss goals of care — Clarify priorities: mobility, cognition, independence

Establish advance care planning — Identify healthcare proxy, discuss preferences

Join support group — CurePSP family support programs

Consider respite care planning — Prepare for future caregiver support needs

118.10 Cross-Links

[Neuropsychiatric and Cognitive Management](#neuropsychiatric-and-cognitive-management)
[Caregiver Support and Resources](#caregiver-support-and-resources)
[Autonomic Dysfunction Management](#autonomic-dysfunction-management)
[Sleep Disorders Management](#sleep-disorders-management)
[Clinical Trial Navigation](#clinical-trial-navigation)
[Neurodegenerative Disease Staging](#neurodegenerative-disease-staging)
[Financial and Insurance Guidance](#financial-and-insurance-guidance)

118.11 References

[^PRO1]: Martinez-Martin P et al., Quality of life in Parkinson's disease: Validation of the PDQ-39 in English (1999). Movement Disorders. 1999;14(5):746-753.

[^PRO2]: Schrag A et al., The PSPRS: A rating scale for progressive supranuclear palsy (2003). Brain. 2003;126(11):2373-2388.

[^PRO3]: Cubo E et al., Comparison of the psychometric properties of the PDQ-39 and the SF-36 in Parkinson's disease (2000). Journal of Neurology Neurosurgery Psychiatry. 2000;69(1):95-100.

[^PRO4]: Zarit SH et al., The Zarit Burden Interview: A new measure of subjective burden (1980). Clinical Gerontologist. 1980;1(3):35-43.

[^PRO5]: Yesavage JA et al., Development and validation of a geriatric depression screening scale (1983). Journal of Psychiatric Research. 1983;17(1):37-49.

[^PRO6]: Koh C et al., Caregiver burden in atypical parkinsonian disorders (2022). Parkinsonism and Related Disorders. 2022;95:86-91.

[^PRO7]: Goetz CG et al., Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (2008). Movement Disorders. 2008;23(15):2129-2170.

[^PRO8]: Rebovich DD et al., Patient-reported outcomes in progressive supranuclear palsy (2021). Neurology. 2021;96(15):e2024-e2034.

slug	therapeutics-clinical-management-guide-cbs-psp
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-656980006a1b
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-clinical-management-guide-cbs-psp'}
_schema_version	1

📗 Cite This Artifact

Clinical Management Guide for CBS/PSP

Clinical Management Guide for CBS/PSP

Clinical Management Guide for CBS/PSP

28. Neuropsychiatric and Cognitive Management

28.1 Cognitive Enhancers

28.1.1 Cholinesterase Inhibitors

28.1.2 Memantine

28.2 Mood Stabilizers and Antidepressants

28.2.1 SSRIs

28.2.2 Other Antidepressants

28.2.3 Mood Stabilizers

28.3 Antipsychotics for PD/PSP/CBS

28.3.1 Pimavanserin (Nuplazid)

28.3.2 Quetiapine (Seroquel)

28.3.3 Clozapine (Clozaril)

28.3.4 What to AVOID

28.4 Sleep Medications

28.4.1 Insomnia

28.4.2 REM Behavior Disorder (RBD)

28.4.3 Excessive Daytime Sleepiness (EDS)

28.5 Anxiety Management

28.5.1 Non-Pharmacological

28.5.2 Pharmacological

28.6 Behavioral Interventions

28.6.1 Cognitive Behavioral Therapy (CBT)

28.6.2 Occupational Therapy (OT)

28.6.3 Speech Therapy

28.6.4 Caregiver Support

28.6.4.1 Caregiver Burnout

28.6.4.2 Support Groups

28.6.4.3 Respite Care Options

28.6.4.4 Home Health Aides

28.6.4.5 Legal and Financial Planning

Advance Directives

Disability Benefits

Long-Term Care Planning

28.6.4.6 Caregiver Coping Strategies

28.6.4.7 Key Resources Summary

28.6.5 Environmental Modifications

28.7 Summary and Recommendations

Neuropsychiatric Management Priorities

Drug Interaction Summary

Key Points for This Patient

36. Pain Management for CBS/PSP

36.1 Types of Pain in CBS/PSP

36.2 Pharmacological Management

First-Line Agents

Second-Line Agents

Agents to Use with Caution

36.3 Non-Pharmacological Approaches

36.4 Pain Assessment Tools

36.5 Treatment Algorithm

36.6 Drug Interactions with Current Medications

36.7 Recommendations for This Patient

36.8 Cross-Links

36.9 References

37. Alternative and Complementary Therapies for CBS/PSP

37.1 Overview of CAM in Neurodegeneration

37.2 Acupuncture

Evidence Summary

Mechanism of Action

Commonly Used Acupoints in Movement Disorders

Safety Considerations

Recommendations for This Patient

37.3 Massage Therapy

Evidence Summary

Techniques Suitable for CBS/PSP

Safety Considerations

Recommendations for This Patient

37.4 Aromatherapy

Evidence Summary

Essential Oils with Relevant Benefits

Safety Considerations

Recommendations for This Patient

37.5 Music Therapy

Evidence Summary

Types of Music Therapy

Recommended Music for CBS/PSP

Safety Considerations